0001171843-22-002237 | 10-K | XBRL Viewer

Stockholders' Equity Note Disclosure [Text Block]

NOTE 4 – STOCKHOLDERS’ EQUITY, STOCK OPTIONS AND WARRANTS

Authorized Shares

At the special meeting on August 17, 2021, the stockholders approved a proposal to increase the number of authorized shares of common stock to 200,000,000 shares of common stock, $0.01 par value. The amendment to the certificate of incorporation to affect this increase was filed on August 17, 2021.

2021 Offerings

In January and February 2021, the Company completed a series of five offerings, all of which were priced at-the-market under applicable NASDAQ rules. The first four offerings were registered direct offerings of common stock under its shelf registration statement, and in each such case, in a concurrent private placement, the Company also issued such investors one warrant to purchase common stock for each two shares purchased in the transaction. Following those four offerings, the Company completed a private placement of common stock, with each investor receiving one warrant to purchase common stock for each two shares purchased in the transaction. In June 2021, the Company completed a registered direct offering of common stock and warrants. The warrants became exercisable on the effective date of an increase in the number of shares of the Company’s authorized common stock, which occurred on August 17, 2021, and expire three years after the initial exercise date. In each case, each such investor warrant is exercisable immediately upon issuance and will expire five and one-half years from the issue date. In each case, the Company paid to the placement agent an aggregate fee equal to 7.5% of the aggregate gross proceeds received by the Company in the offering and a management fee equal to 1% of the aggregate gross proceeds received by the Company in the offering and reimbursed the placement agent for certain non-accountable and out-of-pocket expenses. In addition, the Company granted to the placement agent, or its assigns warrants to purchase 7.5% of the shares sold to investors in the offering at an exercise price equal to 125% of the price of the shares in the transaction, with a term of five years for the registered direct offerings (three years for the June 2021 offering) or five and one-half years for the private placement.

These 2021 offerings were as follows:

Offering Closing Date	Shares		Sale Price per Share*		Investor Warrants		Exercise Price per Share – investor Warrants		Placement Agent Warrants		Exercise Price per Share – Placement Agent Warrants		Gross Proceeds of Offering		Net Proceeds of Offering
January 12, 2021 (registered direct)		3,650,840	$	0.842		1,825,420	$	0.80		273,813	$	1.0525	$	3,074,007	$	2,731,767
January 21, 2021 (registered direct)		2,200,000	$	1.00		1,100,000	$	1.00		165,000	$	1.25	$	2,200,000	$	1,932,050
January 26, 2021 (registered direct)		3,414,970	$	1.20		1,707,485	$	1.20		256,123	$	1.50	$	4,097,964	$	3,668,687
February 16, 2021 (registered direct)		4,222,288	$	1.75		2,111,144	$	2.00		316,672	$	2.1875	$	7,389,004	$	6,679,989
February 23, 2021 (private placement)		9,043,766	$	1.95		4,521,883	$	2.00		678,282	$	2.4375	$	17,635,344	$	16,064,739
June 16, 2021 (registered direct)		15,520,911	$	1.375		15,520,911	$	1.25		1,164,068	$	1.71875	$	21,341,252	$	19,446,296
Total		38,057,775				26,786,843				2,853,958			$	55,737,571	$	50,523,528

* Sale price includes one share and a warrant to purchase one-half share (or one whole share in the case of the June 16, 2021 offering).

2021 Warrant Exercises

During the year ended December 31, 2021, the holders of outstanding investor warrants have exercised such warrants for the total purchase of 5,269,059 shares at a weighted average exercise price of $0.86 per share, for total proceeds of $4,513,871.

Equity Line

On October 24, 2019, the Company entered into an equity purchase agreement with an investor, providing for an equity financing facility. Upon the terms and subject to the conditions in the purchase agreement, the investor is committed to purchase shares having an aggregate value of up to $15,000,000 of the Company’s common stock for a period of up to three years. The Company issued to the investor 104,651 commitment shares at a fair market value of $450,000 for entering into the agreement. From time to time during the three-year commitment period, provided that the closing conditions are satisfied, the Company may provide the investor with put notices to purchase a specified number of shares subject to certain limitations and conditions and at specified prices, which generally represent discounts to the market price of the common stock. During the year ended December 31, 2020, the Company issued 4,231,073 shares of common stock valued at $4,891,348 pursuant to the equity line. As of December 31, 2021, there was $9,113,829 of remaining available balance under the equity line, subject to shareholder approval required for additional purchases, as well as requirements for market conditions including trading volume and stock price, and subject to other limitations. During the year ended December 31, 2021, the Company issued 647,504, shares of its common stock valued at $675,590 pursuant to the equity line.

Series D Preferred Stock

In April 2019, the Company issued 3,500,000 shares of Series D preferred stock to Helomics as part of its acquisition of Helomics. Each share of Series D preferred stock is subject to automatic conversion, whereby each such share converts automatically on a 10:1 basis into a share of the Company’s common stock upon the earlier of (1) the consummation of any fundamental transaction (e.g., a consolidation or merger, the sale or lease of all or substantially all of the assets of Predictive or the purchase, tender or exchange offer of more than 50% of the outstanding shares of voting stock of Predictive,) or (2) the one-year anniversary of the issuance date. On April 4, 2020, 3,500,000 shares of Series D convertible preferred stock were converted into 350,004 shares of common stock.

Series E Convertible Preferred Stock

In June through September 2019, the Company entered into a private placement securities purchase agreement with investors for shares of Series E convertible preferred stock. The Company issued 258 preferred shares. Each preferred shareholder had the right to convert each Series E convertible preferred share into 0.056857% of the issued and outstanding shares of common stock immediately prior to conversion for each share of Series E convertible stock, beginning six months after the initial close date of June 13, 2019. On the date that is 12 months after the initial closing date, the Company has the option to convert the preferred shares into common stock upon the same terms and limitations as the above optional conversion. The preferred shares included a contingent beneficial conversion amount of $289,935, representing the intrinsic value of the shares at the time of issuance. The Company determined the Series E convertible preferred stock should be classified as permanent equity and the beneficial conversion feature amount was accreted through the earliest redemption date of December 13, 2019.

During the first quarter of 2020, 50 shares of Series E convertible preferred stock were converted into 141,191 shares of common stock. In May 2020, we notified the holders of our Series E Convertible Preferred Stock of our election to convert the outstanding shares of Series E Stock into common stock effective on June 13, 2020 pursuant to the terms of the Series E Stock. Prior to the conversion, there were 207.7 shares of Series E Stock outstanding. Each share of Series E Stock converted into 0.056857% of the issued and outstanding shares of common stock immediately prior to conversion; therefore, the 207.7 outstanding shares of Series E Stock on June 13, 2020 converted into 1,257,416 shares of common stock equal to 11.8% of the outstanding shares of common stock as of June 12, 2020.

March 2020 Private Placement

On March 18, 2020, we sold and issued to private investors (i) 260,000 shares of common stock, at a sale price of $2.121 per share; (ii) prefunded warrants to acquire 1,390,166 shares of common stock, sold at $2.12 per share and exercisable at an exercise price of $0.001 per share; (iii) Series A warrants to acquire 1,650,166 shares of Common Stock at $1.88 per share, exercisable immediately and terminating five and one-half years after the date of issuance; and (iv) Series B warrants to acquire 1,650,166 shares of Common Stock at $1.88 per share, exercisable immediately and terminating two years after the date of issuance. See below for amendment dated September 23, 2020.

In addition, and in lieu of common shares, the investors also purchased prefunded warrants to purchase 1,390,166 shares of common stock at a purchase price of $2.12 per prefunded warrant, which represents the per share offering price, minus the $0.0001 per share exercise price of each such prefunded warrant. As a result of the prefunded warrants exercise price being of a nominal amount, these warrants were included as outstanding shares within our earnings per share calculation during the period from purchase through to exercise during the second quarter 2020.

The sale of the offering shares, prefunded warrants and A and B warrants resulted in gross proceeds of $3,498,612 and net proceeds of $3,127,818 after deducting the placement agent fees and estimated offering expenses payable by the Company. The Company agreed to use the net proceeds from the offering for general corporate purposes. The offering closed on March 18, 2020, subject to the satisfaction of customary closing conditions.

Effective September 23, 2020, the Company amended the terms of A and B warrants. Earlier in September, the Company notified the holders of the warrants that the Company would accept an exercise price therefor of $0.8457, amended from the original exercise price of $1.88 per share. The amendment also modified the settlement provisions of the warrants under certain circumstances; this change resulted in a classification change from derivative liability to equity classification. See Note 7 –– Derivatives for discussion of A, B and agent warrants accounted for as derivative liabilities prior to September 23, 2020.

Dr. Schwartz Note Exchange

Effective as of April 21, 2020, the Company and Carl Schwartz, entered into an exchange agreement relating to a promissory note of the Company dated January 31, 2020 issued by the Company in the principal amount of $2,115,000. Pursuant to the exchange agreement, Dr. Schwartz was issued 1,583,481 shares of newly issued common stock at an exchange rate of $1.43 per share. See Note 5 – Notes Payable.

May 2020 Registered Direct Offering and Concurrent Private Placement of Warrants

During May 2020, the Company entered into a securities purchase agreement with certain accredited investors for a registered direct offering of 1,396,826 shares of common stock, par value $0.01 per share. In a concurrent private placement, the Company also issued such investors warrants to purchase up to an aggregate of 1,396,826 shares of common stock. The shares and the warrants were sold at a combined offering price of $1.575 per share and associated warrant. Each warrant is exercisable immediately upon issuance at an exercise price of $1.45 per share and will expire five and one-half years from the issue date. The sale of the offering shares and associated warrants resulted in gross proceeds of $2,200,001 and net proceeds of $1,930,100 after deducting the placement agent fees and offering expenses payable by the Company. The Company used the net proceeds from the offering to repay certain indebtedness and agreed to use the remaining net proceeds from the offering for general corporate purposes. The offering closed on May 8, 2020.

Acquisition from Soluble Therapeutics and BioDtech

On May 27, 2020, the Company entered into an Asset Purchase Agreement with InventaBioTech, Inc. (“InventaBioTech”) and two of its subsidiaries, Soluble Therapeutics, Inc. (“Soluble”), and BioDtech, Inc. (“BioDtech”), and simultaneously completed the acquisition of substantially all of Soluble’s and BioDtech’s assets. In exchange, the Company issued 125,000 shares of common stock and waived all existing claims that the Company has or may have against InventaBioTech (f/k/a CytoBioscience, Inc.), including the nonpayment of $1,290,000 owing by InventaBioTech to the Company. All of the shares issued in the acquisition were deposited into escrow, with 25,000 released upon the six-month anniversary of the closing, 25,000 released upon the nine-month anniversary of the closing, and the remaining shares released on May 26, 2021. Notwithstanding the foregoing, all or some of the escrow shares may be released and returned to the Company for reimbursement in the event that the Company suffers a loss against which InventaBioTech, Soluble, and BioDtech have indemnified the Company pursuant to the Agreement. The Company is also entitled to reclaim 10,000 of the shares if, within six months of the closing, the Company is unable to successfully obtain ownership of all of Soluble’s interest under its license agreement with the UAB Research Foundation. As a result of the acquisition, which was treated as an asset acquisition, the Company recognized fixed assets of $1,492,500.

June 2020 Warrant exercise and issuance

During June 2020, the Company entered into an agreement with certain accredited institutional investors to immediately exercise for cash an aggregate of 1,396,826 of the warrants issued in connection with the May 2020 Registered Direct Offering, exercisable immediately at the exercise price of $1.45 per share of common stock plus an additional $0.125 for each new warrant to purchase up to a number of shares of common stock equal to 100% of the number of shares issued pursuant to the exercise of the existing warrants. The new warrants are exercisable immediately and have a term of five and one-half years and an exercise price per share equal to $1.80. The Company received $2,130,701 in gross proceeds and net proceeds of $1,865,800 after deducting the placement agent fees and offering expenses payable by the Company.

Effective on September 23, 2020, the Company amended the terms of warrants to purchase up to 1,396,826 shares of the Company’s common stock, par value $0.01 per share. The amendment modified the settlement provisions of the warrants under certain circumstances; this change resulted in a classification change from derivative liability to equity classification.

Acquisition of Quantitative Medicine

On July 1, 2020, the Company entered into an Asset Purchase Agreement with Quantitative Medicine LLC (“QM”), a Delaware limited liability company and its owners and simultaneously completed the acquisition of substantially all of QM’s assets owned by Seller. QM is a biomedical analytics and computational biology company that developed a novel, computational drug discovery platform called CoRE. CoRE is designed to dramatically reduce the time, cost, and financial risk of discovering new therapeutic drugs by predicting the main effects of drugs on target molecules that mediate disease. In exchange for QM’s assets, including CoRE, the Company provided consideration in the form of 954,719 shares of common stock, which, when issued, had a fair value of $1,470,267. One half of the shares issued, or 477,359 shares were deposited and held in escrow upon issuance, while 207,144 of the remaining shares were issued to Carnegie Mellon University (“CMU”) in satisfaction of all pre-closing amounts owed to CMU under a technology licensing agreement that was assumed by the Company on the closing date. Half of the shares held in escrow were released on the six-month anniversary of the closing date, and the other half was released on the one-year anniversary of the closing date.

Warrants Issued in Connection with Helomics Acquisition

Effective on September 14, 2020, the Company amended the terms of warrants to purchase up to 1,424,506 shares of the Company’s common stock, par value $0.01 per share, which were issued to certain holders in connection with the Company’s merger transaction with Helomics on April 4, 2019. In September 2020, the Company notified the holders of the warrants that the Company will accept an exercise price of $0.845, equal to the last reported per share price of Common Stock on the NASDAQ Capital Market on September 11, 2020, amended from the original exercise price of $10.00 per share (as adjusted for a one-for-ten (1:10) reverse stock split that was effective on October 29, 2019). The value of the amendment was determined based on the increase in the fair value on the date of modification using the Black Scholes method and equaled $554,287. The amendment was accounted for as a deemed dividend and increased the loss attributable to the common shareholders when calculating earnings per share. The Warrants were issued on April 4, 2019 to holders of warrants in Helomics; the Warrants expire on April 4, 2024. See Note 8 – Loss per Share.

Equity Incentive Plan

The Company has an equity incentive plan, which allows issuance of incentive and non-qualified stock options, stock appreciation rights, stock awards, restricted stock, restricted stock units and performance awards to employees, directors and consultants of the Company, where permitted under the plan. The exercise price for each stock option is determined by the market price on the date of issuance. Vesting requirements are determined by the Board of Directors when granted and currently range from immediate to three years. Options outstanding under this plan have a contractual life of ten years.

At the special meeting on August 17, 2021, the stockholders approved a proposal to increase the reserve shares of common stock authorized for issuance under the Amended and Restated 2012 Stock Incentive Plan by 1,500,000 to 3,250,000 reserve shares.

Options and Warrants

ASC 718, Compensation – Stock Compensation, (“ASC 718”) requires that a company that issues equity as compensation needs to record compensation expense on its statements of net loss that corresponds to the estimated cost of those equity grants. ASC 718 requires companies to estimate the fair value of stock-based payment awards on the date of grant using an option-pricing model or other acceptable means.

The Company determines the grant date fair value of options and warrants using a Black-Scholes option valuation model based upon assumptions regarding risk-free interest rate, expected dividend rate, volatility and estimated term. See Note 1 – Summary of Significant Accounting Policies – Accounting Policies and Estimates.

The following summarizes transactions for stock options and warrants for the periods indicated:

	Stock Options					Warrants
	Number of Shares			Average Exercise Price		Number of Shares			Average Exercise Price

Outstanding at December 31, 2019		766,424		$	11.34		2,171,610		$	15.26

Issued		319,851			1.03		8,097,468			1.55
Forfeited		(72,728	)		10.58		(128,710	)		95.11
Exercised		-			-		(2,786,992	)		0.79

Outstanding at December 31, 2020		1,013,547		$	5.41		7,353,376		$	1.99

Issued		147,230			1.06		29,640,801			1.44
Forfeited		(92,593	)		8.64		-			-
Expired		-			-		(25,233	)		10.00
Exercised		(5,313	)		0.74		(5,269,059	)		0.86

Outstanding at December 31, 2021		1,062,871		$	4.83		31,699,885		$	1.66

At December 31, 2021, 949,615 stock options are fully vested and currently exercisable with a weighted average exercise price of $5.27 and a weighted average remaining term of 8.14 years. There are 31,725,118 warrants that are fully vested and exercisable. At December 31, 2020, 977,420 stock options are fully vested and currently exercisable with a weighted average exercise price of $5.29 and a weighted average remaining term of 8.76 years. There were 7,353,376 warrants that are fully vested and exercisable as of December 31, 2020. Stock-based compensation recognized in 2021 and 2020 was $146,714 and $780,269, respectively. The Company has $70,324 of unrecognized compensation expense related to non-vested stock options that are expected to be recognized over the next 19 months.

The following summarizes the status of options and warrants outstanding at December 31, 2021:

Range of Exercise Prices	Shares		Weighted Average Remaining Life
Options:
0.72 – 1.10		335,876		9.31
$1.15 – 1.64		356,673		8.36
$2.610 – 8.41		214,937		8.15
$10.10 – 5,962.50		155,385		5.99
Total		1,062,871

Warrants:
$0.80-1.72		21,468,599		3.31
$1.80 – 2.18		8,451,287		4.50
$2.25 – 10.00		1,555,778		3.37
$10.71 – 22.50		224,221		2.94
Total		31,699,885

Stock options and warrants expire on various dates from August 2022 to November 2031.

Stock Options and Warrants Granted by the Company

The following table is the listing of outstanding stock options and warrants as of December 31, 2021 by year of grant:

Stock Options:

Year	Shares		Price
2012		114		$1.54	–	$1,500.00
2013		146		1.54	–	5,962.50
2014		84		1.54	–	3,468.75
2015		394		1.54	–	862.50
2016		9,174		1.54	–	42.50
2017		214,555		1.54	–	21.00
2018		78,325		1.54	–	13.50
2019		314,963		1.54	–	7.50
2020		303,199		0.73	–	3.48
2021		141,917		0.72	–	1.47
Total		1,062,871		$0.72	–	$5,962.50

Warrants:

Year	Shares		Price
2017		108,435		$10.71	–	$22.50
2018		196,946		8.36	–	13.125
2019		1,690,286		0.845	–	11.80
2020		2,010,144		0.845	–	2.992
2021		27,694,074		0.80	–	2.992
Total		31,699,885		$0.80	–	$22.50

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Cash flow from operating activities:
Net loss	$ (19,657,174)	$ (25,884,397)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,340,301	1,024,848
Vesting expense	715,938	721,269
Equity instruments issued for management, consulting, and other	205,193	450,901
Amortization of debt discount	244,830	1,246,541
Gain on valuation of equity-linked instruments	(164,902)	(1,765,907)
Income tax benefit	(661,658)	0
Gain on note receivable associated with asset purchase agreement	0	(1,290,000)
Gain on extinguishment of PPP loan	0	(541,867)
Debt extinguishment costs	(0)	1,996,681
Loss on goodwill impairment	2,813,792	12,876,498
Loss on intangible impairment	2,893,548	0
Loss on impairment of software acquired	1,249,727	0
Loss on fixed asset disposal	5,858	120,577
Changes in assets and liabilities:
Accounts receivable	(20,769)	69,913
Inventories	(98,149)	(94,715)
Prepaid expense and other assets	(194,363)	(245,526)
Accounts payable	(350,296)	(1,688,572)
Accrued expenses	(499,563)	700,966
Deferred revenue	54,548	12,644
Other liabilities	85,790	(32,414)
Net cash used in operating activities:	(12,208,929)	(12,257,732)
Cash flow from investing activities:
Acquisition of zPREDICTA, net of cash acquired	(9,590,214)	0
Purchase of fixed assets	(910,429)	(298,379)
Proceeds from sale of fixed assets	0	193,321
Acquisition of intangibles	(51,893)	(62,398)
Loan activities	(55,000)	0
Net cash used in investing activities	(10,607,536)	(167,456)
Cash flow from financing activities:
Proceeds from issuance of common stock, net	50,523,527	0
Proceeds from exercise of warrants into common stock	4,513,871	1,935,855
Proceeds from debt issuance	0	2,761,867
Repayment of debt	(4,162,744)	(1,472,389)
Payment penalties	(1,073,470)	(247,327)
Proceeds from issuance of stock pursuant to equity line	675,590	4,891,348
Issuance of common stock, prefunded warrants, warrants and exchange of warrants, net	0	5,057,919
Repurchase of common stock upon vesting of restricted stock units	(11,526)	0
Other liabilities	(124,500)	25,416
Net cash provided by financing activities	50,340,748	12,952,689
Net increase in cash and cash equivalents	27,524,283	527,501
Cash and cash equivalents at beginning of year	678,332	150,831
Cash and cash equivalents end of year	28,202,615	678,332
Non-cash transactions
Debt Conversion, Converted Instrument, Amount	0	267,328
Warrants issued pursuant to debt issuance	$ 0	$ 179,324
Shares issued pursuant to CEO note conversion and accrued interest and exchange agreement (in shares)	0	2,322,878
Shares issued pursuant to former CEO per agreement related to accrued interest	$ 143,573	$ 0
Fixed assets acquired for notes receivable and common stock	0	2,962,767
Increase to operating lease right of use asset and lease liability due to new and modified leases	77,128	1,417,077
Put and conversion derivative from debt issuance and modification	0	636,563
Inducement shares issued pursuant to convertible debt	514,011	0
Fixed assets acquired for financing arrangements	0	113,192
Cash paid during the period for:
Interest paid on debt	690,508	145,831
Conversion of Series D Preferred Stock to Common Stock [Member]
Non-cash transactions
Preferred stock conversions	0	35,000
Conversion of Series E Preferred Stock [Member]
Non-cash transactions
Preferred stock conversions	0	13,983
Stock Issued for Convertible Debt [Member]
Non-cash transactions
Shares issued pursuant to convertible debt	0	1,028,354
Stock Issued for Debt [Member]
Non-cash transactions
Shares issued pursuant to convertible debt	$ 0	$ 140,555

Note 3 - Inventories (Tables)

12 Months Ended

Dec. 31, 2021

Schedule of Inventory, Current [Table Text Block]

	December 31, 2021		December 31, 2020

Finished goods	$	193,287	$	95,898
Raw materials		183,410		151,366
Work-In-Process		10,987		42,271
Total	$	387,684	$	289,535

Note 1 - Summary of Significant Accounting Policies (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash and Cash Equivalents, at Carrying Value, Ending Balance	$ 28,202,615	$ 678,332
Long-term Debt, Total	0
Accounts Receivable, Allowance for Credit Loss, Current	0	0
Impairment of Intangible Assets (Excluding Goodwill), Total	2,893,548	0
Impairment of Intangible Assets, Software Acquired	1,249,727	0
Accounts Receivable, after Allowance for Credit Loss, Total	354,196	256,878
Contract with Customer, Liability, Total	186,951	53,028
Research and Development Expense, Total	315,850	$ 372,710
Unrecognized Tax Benefits, Ending Balance	0
Other Intangible Assets [Member]
Impairment of Intangible Assets (Excluding Goodwill), Total	$ 0

Note 12 - Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Property, Plant, and Equipment Gross	$ 4,579,909	$ 5,154,547
Less: Accumulated depreciation	2,068,338	1,331,847
Total fixed assets, net	2,511,571	3,822,700
Office Equipment [Member]
Property, Plant, and Equipment Gross	517,488	1,862,669
Laboratory Equipment [Member]
Property, Plant, and Equipment Gross	3,456,091	2,811,011
Leasehold Improvements [Member]
Property, Plant, and Equipment Gross	428,596	315,297
Manufacturing Tooling [Member]
Property, Plant, and Equipment Gross	121,120	108,956
Demo Equipment [Member]
Property, Plant, and Equipment Gross	$ 56,614	$ 56,614

Note 12 - Property, Plant and Equipment (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Impairment of Intangible Assets (Excluding Goodwill), Total	$ 2,893,548	$ 0
Impairment of Intangible Assets, Software Acquired	1,249,727	0
Depreciation, Total	965,973	$ 711,139
Other Finite-lived Intangible Assets [Member]
Impairment of Intangible Assets (Excluding Goodwill), Total	$ 0

Note 2 - zPredicta Acquisition

12 Months Ended

Dec. 31, 2021

Business Combination Disclosure [Text Block]

NOTE 2 – zPREDICTA ACQUISITION

On November 24, 2021, the Company entered into an Agreement and Plan of Merger (the “Agreement”) among the Company, a wholly-owned subsidiary of the Company (the “Merger Sub”), zPREDICTA, and a representative for certain parties who held interests in zPREDICTA. Also on November 24, 2021, the Company acquired zPREDICTA through the merger of Merger Sub with and into zPREDICTA, with zPREDICTA surviving as a wholly-owned subsidiary of the Company.

As consideration for the acquisition, the stockholders and certain holders of interests in zPREDICTA as of immediately prior to the transaction collectively received consideration of approximately $10.0 million in cash. The Agreement contains customary and negotiated representations, warranties, and indemnity provisions.

The acquisition costs of $895,297 related to the acquisition are presented in legal, accounting and consulting expenses within general and administrative expenses in the accompanying consolidated statements of net loss.

The following table summarizes the acquisition date fair values of assets acquired and liabilities assumed, and the consideration transferred:

Cash consideration	$	10,015,941

Assets acquired:
Cash		425,727
Accounts receivable		76,549
Prepaid expenses		25,733
Intangible assets		3,780,000

Liabilities assumed:
Accrued expenses		(408,825	)
Deferred tax liability		(661,658	)
Deferred revenue		(79,375	)

Goodwill	$	6,857,790

The purchase price allocation has been derived from estimates. The Company’s judgements used to determine the estimated fair value assigned to each class of assets acquired and liabilities assumed can materially affect the consolidated operations of the consolidated Company. The total purchase price has been allocation to identifiable assets acquired and liabilities assumed based upon valuation studies and procedures performed to date. The fair value and useful life for the intangible assets are (a) tradename $80,000 b) developed technology $3,500,000 and c) customer relationships $200,000 with useful lives of 4 years, 10 years and 10 years, respectively all using a straight-line method.

The Company acquired zPREDICTA through a non-taxable reverse triangular merger combination. As part of purchase accounting there was $3,780,000 in fair value assigned to purchased intangibles which the Company established a related deferred tax liability as a result of the stock merger combination that offset the acquired deferred assets including NOL’s and other temporary timing differences.

Identifiable Intangible Assets

The Company acquired intangible assets related to trademarks for the acquired zPREDICTA trade name with an estimated fair market value of $80,000. The fair values of the asset were determined by the relief-from-royalty method under the income approach. The Company determined the asset is a finite lived asset. The useful life of the tradename has a remaining useful life of 4 years as of December 31, 2021.

The Company acquired intangible assets with a useful life of 10 years and an estimated value of $200,000 related to customer relationships stemming from stable and predictable cash flow streams associated with customers. zPREDICTA’s customer base includes contract research partnerships with pharmaceutical, diagnostic, biotechnology, and research companies. The customer relationships were valued using the distributor method under the income approach.

The Company acquired intangible assets with a useful life of 10 years and an estimated value of $3,500,000 related to developed technology stemming from the 3D tumor model technology. Since the model technology was identified as the primary asset, this technology was valued using the multi-period excess earnings method under the income approach.

Goodwill

Goodwill of $6,857,790 was recognized in the zPREDICTA acquisition and represents the excess of the consideration transferred over the fair values of assets acquired and liabilities assumed and represents the future economic benefits and synergies arising from the transaction. None of the goodwill will be deductible for income tax purposes. See Note 10 – Goodwill and Intangibles.

Financial Results

The financial results of zPREDICTA since the acquisition date have been included in the Company’s accompanying consolidated statements of net loss.

Pro Forma

The following pro forma information presents the combined results of operations of the Company and zPREDICTA as if the acquisition of zPREDICTA had been completed on January 1, 2020, with adjustments to give effect to pro forma events that are directly attributable to the acquisition.

	2021			2020
	Unaudited			Unaudited
Revenue	$	2,429,786		$	1,815,560
Net loss attributable to common shareholders	$	(18,878,432	)	$	(26,946,564	)

The primary adjustments include the inclusion of the revalued amortization for zPREDICTA intangible assets. The unaudited pro forma results do not reflect any operating efficiencies or potential cost savings which may result from the consolidation of operations. Accordingly, these unaudited pro forma results are presented for informational purposes only and are not necessarily indicative of what the actual results of operations of the combined company would have been if the acquisition had occurred at the beginning of those respective time periods, nor are they indicative of future results of operations.

There are certain portions of purchase accounting, specifically Section 382 for Tax Loss Carryforwards, which take place after a company has undergone a shift in ownership, that the Company has not completed yet and may have a significant impact on the financial statements.

Note 6 - Notes Payable (Details Textual) - USD ($)								1 Months Ended				3 Months Ended			12 Months Ended
Note 6 - Notes Payable (Details Textual) - USD ($)	Mar. 01, 2021	Feb. 24, 2021	Apr. 21, 2020	Apr. 20, 2020	Mar. 19, 2020	Feb. 05, 2020	Sep. 28, 2018	Jan. 31, 2020	Sep. 30, 2019	Feb. 27, 2019	Nov. 30, 2018	Dec. 31, 2020	Sep. 30, 2020	Mar. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Apr. 05, 2020	Mar. 05, 2020	Jul. 15, 2019	Dec. 31, 2018
Debt Instrument, Face Amount												$ 4,676,755			$ 0	$ 4,676,755
Gain (Loss) on Extinguishment of Debt, Total															(0)	541,867
Payments for Penalties															1,073,470	247,327
Debt Instrument, Unamortized Discount, Total												244,830			0	244,830
Repayments of Debt															4,162,744	1,472,389
Debt Conversion, Converted Instrument, Amount															0	$ 267,328
Chief Executive Officer [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)								50,000
Investor of Promissory Note [Member]
Stock Issued During Period, Shares, New Issues (in shares)						46,875
Dr. Schwartz [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)		100,401
Shares Issued, Price Per Share (in dollars per share)			$ 1.43
Stock Issued, Agreement, Not to be Transferred or Sold For Three Months (in shares)			766,740
Stock Issued, Agreement, Not to be Transferred or Sold for Six Months (in shares)			766,741
Dr. Schwartz [Member] \| DrSchwartz Notes [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)		143,573
Conversion of Bridge Loan to Common Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)																170,000
Promissory Note Exchange Agreement [Member] \| Chief Executive Officer [Member]
Debt Conversion, Converted Instrument, Amount								$ 2,115,000
Conversion of Promissory Note Into Common Stock [Member]
Shares Issued, Price Per Share (in dollars per share)			$ 1.43
Bridge Loan Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)							107,178
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)							$ 11.55
Warrant for Promissory Notes [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)									68,237
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)									$ 6.21
Warrants Issued With Promissory Note, One [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)						94,631
Warrants Issued With Promissory Note, Two [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)																		92,700
Warrants Issued With Promissory Note, Three [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)																	92,700
Warrants Issued With Promissory Note [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)						$ 2.992
Dr. Schwartz Notes Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)																			22,129
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)																			$ 8.36
Convertible Promissory Note [Member]
Debt Instrument, Face Amount												1,721,776			$ 0	$ 1,721,776
Promissory Note [Member] \| Chief Executive Officer [Member]
Debt Instrument, Interest Rate, Stated Percentage								12.00%
Second Promissory Note [Member]
Debt Instrument, Face Amount						$ 1,450,000
Debt Instrument, Interest Rate, Stated Percentage						8.00%
Debt Conversion, Original Debt, Amount												$ 503,354
Debt Conversion, Converted Instrument, Shares Issued (in shares)												1,075,911
Proceeds from Short-term Debt, Total						$ 400,000
Payments for Penalties																0
Penalties Accrued												$ 314,011				314,011
Short-term Debt, Total												1,464,146				1,464,146
Debt Instrument, Unamortized Discount, Total												0				0
Debt Instrument, Convertible, Conversion Price (in dollars per share)						$ 2.589
Dr. Schwartz Note, One [Member]
Debt Instrument, Face Amount																				$ 370,000
Debt Instrument, Unamortized Discount, Total																				$ 63,028
Proceeds from Related Party Debt											$ 370,000
DrSchwartz Notes [Member]
Debt Instrument, Face Amount			$ 2,115,000					$ 2,115,000											$ 1,920,000
Debt Instrument, Interest Rate, Stated Percentage								12.00%
Short-term Debt, Total			2,192,878
Interest Payable			$ 77,878
DrSchwartz Notes [Member] \| Conversion of Promissory Note Into Common Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)			1,583,481
Borrowings Against Equity Line [Member]
Debt Instrument, Face Amount												$ 1,098,684				$ 1,098,684
Debt Instrument, Interest Rate, Stated Percentage												8.00%				8.00%
Proceeds from Short-term Debt, Total																$ 1,020,000
Payments for Penalties																247,327
Short-term Debt, Total												$ 0				0
Repayments of Short-term Debt, Total																1,459,973
Bridge Notes [Member] \| Convertible Promissory Note [Member]
Debt Instrument, Face Amount							$ 2,297,727
Proceeds from Notes Payable, Total							$ 2,000,000
Stock Issued During Period, Shares, New Issues (in shares)							65,000			16,667
Debt Instrument, Interest Rate, Stated Percentage							8.00%
Debt Instrument, Increase (Decrease), Net, Total										$ 344,659
Debt Conversion, Original Debt, Amount																267,328
Securities Purchase Agreements [Member] \| Promissory Note [Member]
Debt Instrument, Face Amount					$ 300,000				$ 847,500
Stock Issued During Period, Shares, New Issues (in shares)									8,857
Debt Instrument, Interest Rate, Stated Percentage									8.00%
Debt Conversion, Original Debt, Amount												$ 525,000
Debt Conversion, Converted Instrument, Shares Issued (in shares)												1,136,448
Proceeds from Short-term Debt, Total									$ 700,000
Stock Issued During Period, Shares, Extension of Notes Payable (in shares)					30,000
Gain (Loss) on Extinguishment of Debt, Total													$ (345,000)	$ (300,000)
Payments for Penalties																0
Penalties Accrued												$ 320,542				320,542
Short-term Debt, Total												1,490,833				1,490,833
Debt Instrument, Unamortized Discount, Total												$ 244,830				$ 244,830
Securities Purchase Agreements [Member] \| Promissory Note [Member] \| Maturity Extension to March 31, 2021 [Member]
Gain (Loss) on Extinguishment of Debt, Total													(690,000)
Securities Purchase Agreements [Member] \| Second Promissory Note [Member]
Gain (Loss) on Extinguishment of Debt, Total													(172,500)
Securities Purchase Agreements [Member] \| Second Promissory Note [Member] \| Maturity Extension to March 31, 2021 [Member]
Gain (Loss) on Extinguishment of Debt, Total													$ (345,000)
Debt Issued in September 2018, September, 2019, and February 2020 [Member]
Repayments of Debt	$ 5,906,802
Paycheck Protection Program CARES Act [Member]
Proceeds from Issuance of Long-term Debt, Total				$ 541,867

Note 13 - Segments (Tables)

12 Months Ended

Dec. 31, 2021

Schedule of Segment Reporting Information, by Segment [Table Text Block]

	Year Ended December 31, 2021
	Skyline			Helomics			Soluble			zPREDICTA			Corporate			Total
Revenue	$	1,169,811		$	13,367		$	233,293		$	90		$	4,119		$	1,420,680
Depreciation and Amortization		(30,002	)		(886,642	)		(366,713	)		(40,625	)		(16,319	)		(1,340,301	)
Impairment expense – goodwill		-			(2,813,792	)		-			-			-			(2,813,792	)
Impairment expense – intangibles		-			(2,893,548	)		-			-			-			(2,893,548	)
Impairment expense – acquired software		-			(1,249,727	)		-			-			-			(1,249,727	)
Net loss	$	(520,822	)	$	(11,326,948	)	$	(1,251,564	)	$	531,446		$	(7,089,286	)	$	(19,657,174	)

	December 31, 2021
	Skyline		Helomics		Soluble		zPREDICTA		Corporate		Total
Assets	$	906,977	$	1,802,792	$	1,742,445	$	10,782,568	$	28,536,489	$	43,771,271

	Year Ended December 31, 2020
	Skyline			Helomics			Soluble			Corporate			Total
Revenue	$	1,185,214		$	64,188		$	2,870		$	-		$	1,252,272
Depreciation and Amortization		(38,310	)		(761,105	)		(184,071	)		(41,362	)		(1,024,848	)
Impairment expense		-			(12,876,498	)		-			-			(12,876,498	)
Net loss	$	(1,132,251	)	$	(15,112,131	)	$	(671,367	)	$	(8,968,648	)	$	(25,884,397	)

	December 31, 2020
	Skyline		Helomics		Soluble		Corporate		Total
Assets	$	1,191,439	$	9,773,902	$	1,883,585	$	211,510	$	13,060,436

Note 4 - Stockholders' Equity, Stock Options and Warrants - Summary of Status of Options and Warrants Outstanding (Details)	12 Months Ended
	Dec. 31, 2021 $ / shares shares
Shares, options (in shares) \| shares	1,062,871
Shares, warrants (in shares) \| shares	31,699,885
Minimum [Member]
Warrants issued, exercise price (in dollars per share)	$ 0.80
Maximum [Member]
Warrants issued, exercise price (in dollars per share)	$ 22.50
Warrant One [Member]
Shares, warrants (in shares) \| shares	21,468,599
Weighted average remaining life, warrants (Year)	3 years 3 months 21 days
Warrant One [Member] \| Minimum [Member]
Warrants issued, exercise price (in dollars per share)	$ 80
Warrant One [Member] \| Maximum [Member]
Warrants issued, exercise price (in dollars per share)	$ 1.72
Warrant Two [Member]
Shares, warrants (in shares) \| shares	8,451,287
Weighted average remaining life, warrants (Year)	4 years 6 months
Warrant Two [Member] \| Minimum [Member]
Warrants issued, exercise price (in dollars per share)	$ 1.80
Warrant Two [Member] \| Maximum [Member]
Warrants issued, exercise price (in dollars per share)	$ 2.18
Warrant Three [Member]
Shares, warrants (in shares) \| shares	1,555,778
Weighted average remaining life, warrants (Year)	3 years 4 months 13 days
Warrant Three [Member] \| Minimum [Member]
Warrants issued, exercise price (in dollars per share)	$ 2.25
Warrant Three [Member] \| Maximum [Member]
Warrants issued, exercise price (in dollars per share)	$ 10.00
Warrant Four [Member]
Shares, warrants (in shares) \| shares	224,221
Weighted average remaining life, warrants (Year)	2 years 11 months 8 days
Warrant Four [Member] \| Minimum [Member]
Warrants issued, exercise price (in dollars per share)	$ 10.71
Warrant Four [Member] \| Maximum [Member]
Warrants issued, exercise price (in dollars per share)	22.50
Stock Options One [Member]
Options, lower limit (in dollars per share)	0.72
Options, upper limit (in dollars per share)	$ 1.10
Shares, options (in shares) \| shares	335,876
Weighted average remaining life, options (Year)	9 years 3 months 21 days
Stock Options Two [Member]
Options, lower limit (in dollars per share)	$ 1.15
Options, upper limit (in dollars per share)	$ 1.64
Shares, options (in shares) \| shares	356,673
Weighted average remaining life, options (Year)	8 years 4 months 9 days
Stock Options Three [Member]
Options, lower limit (in dollars per share)	$ 2.610
Options, upper limit (in dollars per share)	$ 8.41
Shares, options (in shares) \| shares	214,937
Weighted average remaining life, options (Year)	8 years 1 month 24 days
Stock Options Four [Member]
Options, lower limit (in dollars per share)	$ 10.10
Options, upper limit (in dollars per share)	$ 5,962.50
Shares, options (in shares) \| shares	155,385
Weighted average remaining life, options (Year)	5 years 11 months 26 days

Note 8 - Loss Per Share - Shares Used in Basic and Diluted Loss Per Common Share Computations (Details) - USD ($)

12 Months Ended

Dec. 31, 2021

Dec. 31, 2020

Net loss attributable to common shareholders per common share: basic and diluted calculation

$ (19,657,174)

$ (26,438,684)

Weighted average common shares outstanding-basic (in shares)

^[1]

54,876,044

11,950,154

Effect of diluted stock options, warrants and preferred stock (1) (in shares)

Weighted average common shares outstanding-diluted (in shares)

54,876,044

11,950,154

Loss per common share-basic and diluted (in dollars per share)

$ (0.36)

$ (2.21)

[1]	The following is a summary of the number of underlying shares outstanding at the end of the respective periods that have been excluded from the diluted calculations because the effect on loss per common share would have been anti-dilutive:

Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Note 9 - Income Taxes

12 Months Ended

Dec. 31, 2021

Income Tax Disclosure [Text Block]

NOTE 9 – INCOME TAXES

The provision for income taxes consists of an amount for taxes currently payable and a provision for tax consequences deferred to future periods. Deferred income taxes are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.

The Company recognized an income tax benefit of $661,658 in our consolidated statement of net loss related to the release of valuation allowance as a result of the zPREDICTA business combination. However, due to the cumulative operating losses, the Company determined that a 100% valuation allowance for the net deferred tax assets at December 31st is appropriate.

Actual income tax benefit differs from statutory federal income tax benefit as follows:

	Year Ended December 31,
	2021			2020
Statutory federal income tax benefit	$	4,266,955		$	5,434,463
State tax benefit, net of federal taxes		793,282			578,746
Foreign tax benefit		-			62,146
Foreign operations tax rate differential		-			(44,120	)
State rate adjustment		5,153			65,112
Nondeductible/nontaxable items		(260,768	)		(268,968	)
Goodwill impairment		(605,420	)		(2,762,014	)
NOL adjustments		(612,588	)		(1,141,662	)
Other		150,083			(461,020	)
Valuation allowance increase		(3,075,039	)		(1,462,683	)
Total income tax benefit	$	661,658		$	-

Deferred taxes consist of the following:

	December 31, 2021			December 31, 2020
Deferred tax assets:
Noncurrent:
Inventory	$	-		$	7,196
Compensation accruals		58,829			63,846
Accruals and reserves		50,537			162,628
Deferred revenue		26,198			11,641
Charitable contribution carryover		1,095			4,331
Derivatives		27,859			63,145
Intangibles		700,876			295,941
Right of use asset		18,543			13,861
NSQO compensation		1,602,429			1,738,217
NOL and credits		82,814,111			80,038,356
Total deferred tax assets		85,300,477			82,400,860

Deferred tax liabilities:
Noncurrent:
Depreciation		(120,353	)		(295,775	)
Total deferred tax liabilities		(120,353	)		(295,775	)

Net deferred tax assets		85,180,124			82,105,085
Less: valuation allowance		(85,180,124	)		(82,105,085	)
Total	$	-		$	-

The Company has determined, based upon its history, that it is probable that future taxable income may be insufficient to fully realize the benefits of the net operating loss (“NOL”) carryforwards and other deferred tax assets. As such, the Company has determined that a full valuation allowance is warranted. Future events and changes in circumstances could cause this valuation allowance to change.

The acquired NOL carryforwards from zPREDICTA experienced an ownership change as defined in Section 382 of the Internal Revenue Code as a result of the merger. In addition, the Company experienced an ownership change in 2019 with the Helomics acquisition as well as December 2013. As a result, the ability to utilize the Company’s NOLs is limited. The Company may have experienced additional ownership changes since December 2013, but a formal study has not yet been performed. The general limitation rules allow the Company to utilize its NOLs subject to an annual limitation that is determined by multiplying the federal long-term tax-exempt rate by the Company’s value immediately before the ownership change.

At December 31, 2020, the Company had $297,735,754 of gross NOLs to reduce future federal taxable income, the majority of which are expected to be available for use in 2021, subject to the Section 382 limitation described above. The federal NOL’s of $261,455,216 expire beginning in 2022 if unused and $36,280,538 will carryforward indefinitely. The Company also had $222,290,524 of gross NOLs to reduce future state taxable income at December 31, 2020. The state NOL’s will expire beginning in 2021 if unused. The Company dissolved its Belgium subsidiary in 2020 and all carryforward tax losses will be eliminated on the final 2020 Belgium tax return filed. The Company's net deferred tax assets, which include the NOLs, are subject to a full valuation allowance. At December 31, 2020, the federal, state, and foreign valuation allowances were $59,913,739, $22,191,346, and $0, respectively.

At December 31, 2021, the Company had $308,990,822 of gross NOLs to reduce future federal taxable income, the majority of which are expected to be available for use in 2022, subject to the Section 382 limitation described above. The federal NOL’s of $259,490,005 expire beginning in 2023 if unused and $49,500,817 will carryforward indefinitely. The Company also had $227,277,399 of gross NOLs to reduce future state taxable income at December 31, 2021. The state NOL’s will expire beginning in 2022 if unused. The Company's net deferred tax assets, which include the NOLs, are subject to a full valuation allowance. At December 31, 2021, the federal and state valuation allowances were $62,034,750 and $23,145,374 respectively.

Tax years subsequent to 2001 remain open to examination by federal and state tax authorities due to unexpired net operating loss carryforwards.

The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax positions will be sustained on examination by taxing authorities, based on technical merits of the positions. The Company has identified no income tax uncertainties.

The Company recognizes interest and penalties on unrecognized tax benefits as well as interest received from favorable tax settlements within income tax expense. At December 31, 2021 and 2020, the Company recorded no accrued interest or penalties related to uncertain tax positions.

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Note 13 - Segments (Details Textual)	12 Months Ended
Note 13 - Segments (Details Textual)	Dec. 31, 2021
Number of Operating Segments	4

Consolidated Balance Sheets - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Current Assets:
Cash and cash equivalents	$ 28,202,615	$ 678,332
Accounts Receivable	354,196	256,878
Inventories	387,684	289,535
Prepaid Expense and Other Assets	513,778	289,490
Total Current Assets	29,458,273	1,514,235
Fixed Assets, net	2,511,571	3,822,700
Intangibles, net	3,962,118	3,398,101
Lease Right-of-Use Assets	814,454	1,395,351
Other Long-Term Assets	167,065	116,257
Goodwill	6,857,790	2,813,792
Total Assets	43,771,271	13,060,436
LIABILITIES AND STOCKHOLDERS' EQUITY
Accounts Payable	1,021,774	1,372,070
Notes Payable – Net of Discounts of $0 and $244,830	0	4,431,925
Accrued Expenses and other liabilities	1,262,641	2,588,047
Derivative Liability	129,480	294,382
Deferred Revenue	186,951	53,028
Lease Liability – Net of Long-Term Portion	639,662	597,469
Total Current Liabilities	3,240,508	9,336,921
Other Long Term Liabilities	25,415	235,705
Lease Liability, long-term portion	239,664	845,129
Total Liabilities	3,505,587	10,417,755
Stockholders’ Equity:
Common Stock, $.01 par value, 200,000,000 and 100,000,000 authorized, 65,614,597 and 19,804,787 outstanding	656,146	198,048
Additional Paid-in Capital	167,649,028	110,826,949
Accumulated Deficit	(128,040,282)	(108,383,108)
Total Stockholders' Equity	40,265,684	2,642,681
Total Liabilities and Stockholders' Equity	43,771,271	13,060,436
Series B Convertible Preferred Stock [Member]
Stockholders’ Equity:
Series B Convertible Preferred Stock, $.01 par value, 2,300,000 authorized, 79,246 and 79,246 shares outstanding	$ 792	$ 792

Note 1 - Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2021

Property Plant and Equipment Useful Life [Table Text Block]

	Years
Computers, software and office equipment	3	-	10
Leasehold improvements (1)	2	-	5
Manufacturing tooling	3	-	7
Laboratory equipment	4	-	10
Demo equipment		3

Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]

	For the Year Ended December 31,
	2021			2020
	Stock Options
Expected dividend yield		0.0%			0.0%
Expected stock price volatility	84.8%	-	89.6%	82.6%	-	87%
Risk-free interest rate	0.93%	-	1.66%	0.13%	-	1.78%
Expected life (years)		10			10
	*Warrants*
Expected dividend yield		0.0%			0.0%
Expected stock price volatility		84.8%		82.6%	-	87%
Risk-free interest rate	0.42%	-	0.69%	0.135%	-	0.79%
Expected life (years)	5/		5.5	5/		5.5

Note 7 - Derivatives (Tables)

12 Months Ended

Dec. 31, 2021

Schedule of Derivative Liabilities at Fair Value [Table Text Block]

Derivative liability balance at December 31, 2019	$	50,989
Derivative instrument recognized for A, B and Agent Warrants		2,669,995
Derivative instrument related to Promissory Note 2020		120,921
Derivative instrument recognized for May 2020 Warrants		1,324,184
Derivative instrument recognized for June 2020 Warrants		1,749,721
Derivative instrument related to Promissory Note 2020		20,542
Reclassification of Warrant liabilities to Equity on exercise		(1,701,756	)
Reclassification of Warrant liabilities to Equity		(2,669,408	)
Derivative instrument related to September 30 debt amendments		495,100
Gain recognized to revalue derivative instrument at fair value		(1,765,906	)
Derivative liability balance at December 31, 2020	$	294,382
Gain recognized to revalue derivative instrument at fair value		(164,902	)
Derivative liability balance at December 31, 2021	$	129,480

Consolidated Balance Sheets (Parentheticals) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Discount of note payable	$ 0	$ 244,830
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	200,000,000	100,000,000
Common stock, shares outstanding (in shares)	65,614,597	19,804,787
Series B Convertible Preferred Stock [Member]
Preferred stock, shares authorized (in shares)	2,300,000	2,300,000
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares outstanding (in shares)	79,246	79,246

Note 6 - Notes Payable - Notes Payable (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Notes Payable, Gross	$ 0	$ 4,676,755
Debt Instrument, Unamortized Discount, Total	0	244,830
Notes Payable	0	4,431,925
Convertible Promissory Note [Member]
Notes Payable, Gross	0	1,721,776
Promissory Note, One [Member]
Notes Payable, Gross	0	1,490,833
Promissory Note, Two [Member]
Notes Payable, Gross	$ 0	$ 1,464,146

Note 14 - Related Party Transactions (Details Textual) - USD ($)	May 01, 2019	Apr. 01, 2019
Director [Member]
Related Party Transaction, Monthly Cash Payment	$ 13,500	$ 12,000

Note 9 - Income Taxes - Components of Deferred Income Taxes (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Inventory	$ 0	$ 7,196
Compensation accruals	58,829	63,846
Accruals and reserves	50,537	162,628
Deferred revenue	26,198	11,641
Charitable contribution carryover	1,095	4,331
Derivatives	27,859	63,145
Intangibles	700,876	295,941
Right of use asset	18,543	13,861
NSQO compensation	1,602,429	1,738,217
NOL and credits	82,814,111	80,038,356
Total deferred tax assets	85,300,477	82,400,860
Depreciation	(120,353)	(295,775)
Total deferred tax liabilities	(120,353)	(295,775)
Net deferred tax assets	85,180,124	82,105,085
Less: valuation allowance	(85,180,124)	(82,105,085)
Total	$ 0	$ 0

Note 10 - Goodwill and Intangibles - Estimated Future Amortization Expense (Details)	Dec. 31, 2021 USD ($)
2022	$ 411,609
2023	411,610
2024	411,610
2025	409,526
2026	391,610
Thereafter	1,926,153
Total	$ 3,962,118

Consolidated Statements of Net Loss - USD ($)	12 Months Ended
Consolidated Statements of Net Loss - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Revenue	$ 1,420,680	$ 1,252,272
Cost of goods sold	487,024	447,192
Gross profit	933,656	805,080
General and administrative expense	10,932,125	10,351,973
Operations expense	2,698,565	2,351,709
Sales and marketing expense	774,530	584,937
Loss on goodwill impairment	2,813,792	12,876,498
Loss on impairment intangibles	2,893,548	0
Loss on impairment of software acquired	1,249,727	0
Total operating loss	(20,428,631)	(25,360,037)
Other income	184,528	843,440
Other expense	(239,631)	(2,427,026)
Loss on early extinguishment of debt	0	(1,996,681)
Gain on derivative instruments	164,902	1,765,907
Gain on notes receivables associated with asset purchase	0	1,290,000
Net loss before income tax benefit	(20,318,832)	(25,884,397)
Income tax benefit	(661,658)	0
Net loss	(19,657,174)	(25,884,397)
Deemed dividend	0	554,287
Net loss attributable to common shareholders	$ (19,657,174)	$ (26,438,684)
Loss per common share - basic and diluted (in dollars per share)	$ (0.36)	$ (2.21)
Weighted average shares used in computation - basic and diluted (in shares)	54,876,044	11,950,154

Note 11 - Leases - Rent Obligation (Details)	Dec. 31, 2021 USD ($)
2022	$ 751,345
2023	188,931
2024	71,420
2025	48,552
Total lease payments	1,060,248
Less interest	180,922
Present value of lease liabilities	$ 879,326

Note 15 - Retirement Savings Plans

12 Months Ended

Dec. 31, 2021

Retirement Benefits [Text Block]

NOTE 15 – RETIREMENT SAVINGS PLANS

The Company has a pre-tax salary reduction/profit-sharing plan under the provisions of Section 401(k) of the Internal Revenue Code, which covers employees meeting certain eligibility requirements. During 2019 and 2018, the Company matched 100% of the employee’s contribution up to 4.0% of their earnings. The employer contribution was $127,953 and $119,555 in 2021 and 2020, respectively. There were no discretionary contributions to the plan in 2021 and 2020.

The entire disclosure for retirement benefits.

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 55
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section S99
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(i)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (o)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (p)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 70
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-URI http://asc.fasb.org/topic&trid=2235017

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 60
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(03)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (q)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(1)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iii)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (l)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(2)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Note 5 - Notes Receivable (Details Textual) - USD ($)	May 27, 2020	Dec. 31, 2019
Other Capitalized Property Plant and Equipment [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment, Total	$ 1,492,500
Asset Purchase Agreement with InventaBiotech and Its Subsidiaries, Soluble and BioDeth [Member]
Stock Issued During Period, Shares, Purchase of Assets (in shares)	125,000
Other Nonoperating Income	$ 1,290,000
CytoBioscience [Member] \| Promissory Notes Receivable [Member]
Financing Receivable, after Allowance for Credit Loss, Total		$ 1,112,524
Notes Receivable, Interest Rate, Stated Percentage		8.00%
Financing Receivable, Allowance for Credit Loss, Ending Balance		$ 1,037,524

Note 3 - Inventories - Schedule of Inventory (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Finished goods	$ 193,287	$ 95,898
Raw materials	183,410	151,366
Work-In-Process	10,987	42,271
Total	$ 387,684	$ 289,535

Note 5 - Notes Receivable

12 Months Ended

Dec. 31, 2021

Financing Receivables [Text Block]

NOTE 5– NOTES RECEIVABLE

The Company had a secured promissory note receivable from CytoBioscience for $1,112,524 (“2017 Promissory Note”), plus interest paid monthly at the per annum rate of (8%) on the principal amount. Unpaid principal and unpaid accrued interest on the note were due and payable on February 28, 2020. In 2019, CytoBioscience and its parent company, InventaBioTech, paid interest in the first quarter due through April 2019. The Company had not received any payments from CytoBioscience since the first quarter of 2019. The Company had evaluated the feasibility of repayment and concluded that it was probable that the Company would be unable to collect all amounts due according to the contractual terms of the receivable. During 2019, the Company recorded a valuation allowance of $1,037,524 related to the notes receivable balance. During 2019, the Company also recorded a loss on this note for the uncollected balance.

Note 8 - Loss Per Share - Antidilutive Securities Excluded from the Diluted Calculations (Details) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-based Payment Arrangement, Option [Member]
Antidilutive Securities (in shares)	1,062,871	1,013,547
Warrant [Member]
Antidilutive Securities (in shares)	31,699,885	7,353,376
Convertible Debt Securities [Member]
Antidilutive Securities (in shares)		1,107,544
Series B Convertible Preferred Stock [Member]
Antidilutive Securities (in shares)	79,246	79,246

Note 10 - Goodwill and Intangibles (Details Textual)	3 Months Ended	9 Months Ended		12 Months Ended
Note 10 - Goodwill and Intangibles (Details Textual)	Dec. 31, 2020 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2020 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Nov. 24, 2021 USD ($)	Dec. 31, 2019 USD ($)	Apr. 04, 2019 USD ($)
Amortization of Intangible Assets, Total				$ 374,328	$ 313,709
Intangibles, net	$ 3,398,101			3,962,118	3,398,101
Impairment of Intangible Assets (Excluding Goodwill), Total				2,893,548	0
Impairment of Intangible Assets, Software Acquired				1,249,727	0
Goodwill, Ending Balance	2,813,792			6,857,790	2,813,792		$ 15,690,290
Goodwill, Impairment Loss	9,879,498	$ 2,813,792	$ 2,997,000	2,813,792	12,876,498
Goodwill, Impaired, Accumulated Impairment Loss	$ 20,976,498	$ 23,790,290			20,976,498
Helomics Holding Corp. [Member]
Goodwill, Decrease in Growth Rate of 0.5 Percent, Reduction in Fair Value					588,000
Goodwill, Increase in Discount Rate of 0.5 Percent, Reduction in Fair Value					$ 988,000
Measurement Input, Expected Cash Flow Term [Member]
Reporting Unit Measurement Input	10	10	20		10
Measurement Input, Long-term Revenue Growth Rate [Member]
Reporting Unit Measurement Input	0.050	4.0	0.030		0.050
Measurement Input, Discount Rate [Member]
Reporting Unit Measurement Input	0.140	15	0.25		0.140
Measurement Input, Risk Premium [Member]
Reporting Unit Measurement Input	0.010		0.10		0.010
Helomics Holding Corp. [Member]
Goodwill, Ending Balance								$ 23,790,290
zPREDICTA [Member]
Goodwill, Ending Balance						$ 6,857,790
Goodwill, Acquired During Period				$ 6,857,790

Note 11 - Leases

12 Months Ended

Dec. 31, 2021

Lessee, Operating Leases [Text Block]

NOTE 11 – LEASES

Our corporate offices are located in Eagan, Minnesota. The lease as amended has a three-year term ended January 31, 2021. We lease 5,773 square feet at this location, of which 2,945 square feet is used for office space and 2,828 is used for manufacturing. The lease was amended subsequent to December 31, 2020 for one additional year until January 31, 2022, and has a second amended six-month term until July 31, 2022. Management and the landlord have orally agreed to further extensions as needed.

The offices of our Helomics subsidiary are located in Pittsburgh, Pennsylvania. The lease, as amended, has a three-year term ending February 28, 2023. We lease 17,417 square feet at this location, of which approximately 1,000 square feet are used for office space and 16,417 square feet is used for laboratory operations.

zPREDICTA’s offices are located in San Jose, California. We lease approximately 1,236 square feet at this location. The lease is month-to-month tenancy.

Soluble Biotech’s offices are located in Birmingham, Alabama. We lease approximately 4,314 square feet at this location. The lease is effective through August 25, 2025.

TumorGenesis’s offices are located in Salem, Massachusetts. We lease approximately 1,450 square feet at this location. The lease is effective through May 31, 2023.

Skyline Medical Europe’s offices were located in Belgium. The Company leased around 2,000 square feet at this location, 750 square feet of which is used for storage and 1,250 square feet is used for office space. The lease was terminated in the fourth quarter of 2020.

Lease expense under operating lease arrangements was $595,669 and $565,581 for 2021 and 2020, respectively.

The following table summarizes other information related to the Company’s operating leases:

	December 31, 2021	December 31, 2020
Weighted average remaining lease term – operating leases in years	1.69	2.33
Weighted average discount rate – operating leases	8%	8%

The Company’s lease obligation as of December 31, 2021 which includes expected lease extensions that are reasonable certain of renewal, are as follows:

2022	$	751,345
2023		188,931
2024		71,420
2025		48,552
Total lease payments		1,060,248
Less interest		180,922
Present value of lease liabilities	$	879,326

Note 4 - Stockholders' Equity, Stock Options and Warrants - Summary of Transactions for Stock Options and Warrants (Details) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Number of Shares Outstanding (in shares)	1,062,871
Warrant [Member]
Number of Shares Outstanding (in shares)	7,353,376	2,171,610
Average Exercise Price Outstanding (in dollars per share)	$ 1.99	$ 15.26
Number of Shares Issued (in shares)	29,640,801	8,097,468
Average Exercise Price Issued (in dollars per share)	$ 1.44	$ 1.55
Number of Shares Forfeited (in shares)	0	(128,710)
Average Exercise Price Forfeited (in dollars per share)	$ 0	$ 95.11
Number of Shares Exercised (in shares)	(5,269,059)	(2,786,992)
Average Exercise Price Exercised (in dollars per share)	$ 0.86	$ 0.79
Expired (in shares)	(25,233)
Expired (in dollars per share)	$ 10.00
Number of Shares Outstanding (in shares)	31,699,885	7,353,376
Average Exercise Price Outstanding (in dollars per share)	$ 1.66	$ 1.99
Share-based Payment Arrangement, Option [Member]
Number of Shares Outstanding (in shares)	1,013,547	766,424
Average Exercise Price Outstanding (in dollars per share)	$ 5.41	$ 11.34
Number of Shares Issued (in shares)	147,230	319,851
Average Exercise Price Issued (in dollars per share)	$ 1.06	$ 1.03
Number of Shares Forfeited (in shares)	(92,593)	(72,728)
Average Exercise Price Forfeited (in dollars per share)	$ 8.64	$ 10.58
Number of Shares Exercised (in shares)	(5,313)	0
Average Exercise Price Exercised (in dollars per share)	$ 0.74	$ 0
Expired (in shares)	0
Expired (in dollars per share)	$ 0
Number of Shares Outstanding (in shares)	1,062,871	1,013,547
Average Exercise Price Outstanding (in dollars per share)	$ 4.83	$ 5.41

Note 10 - Goodwill and Intangibles (Tables)

12 Months Ended

Dec. 31, 2021

Schedule of Finite-Lived Intangible Assets [Table Text Block]

	December 31, 2021										December 31, 2020
	Gross Carrying Costs		Accumulated Amortization			Impairment			Net Carrying Amount		Gross Carrying Costs		Accumulated Amortization			Net Carrying Amount
Patents & Trademarks	$	453,314	$	(230,572	)	$	-		$	222,742	$	401,421	$	(211,110	)	$	190,311
Developed Technology		6,382,000		(432,733	)		(2,485,725	)		3,463,542		2,882,000		(252,175	)		2,629,825
Customer Relationships		645,000		(410,000	)		(37,083	)		197,917		445,000		(259,583	)		185,417
Tradename		478,000		(29,344	)		(370,740	)		77,917		398,000		(5,452	)		392,548
Total	$	7,958,314	$	(1,102,649	)	$	(2,893,548	)	$	3,962,118	$	4,126,421	$	(728,320	)	$	3,398,101

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

Year ending December 31,	Expense
2022	$	411,609
2023		411,610
2024		411,610
2025		409,526
2026		391,610
Thereafter		1,926,153
Total	$	3,962,118

Schedule of Goodwill [Table Text Block]

Goodwill balance at December 31, 2019	$	15,690,290
Impairment		(12,876,498	)
Goodwill balance at December 31, 2020	$	2,813,792
Impairment		(2,813,792	)
Acquisition of zPREDICTA		6,857,790
Goodwill balance at December 31, 2021	$	6,857,790

Note 2 - zPredicta Acquisition (Tables)

12 Months Ended

Dec. 31, 2021

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]

Cash consideration	$	10,015,941

Assets acquired:
Cash		425,727
Accounts receivable		76,549
Prepaid expenses		25,733
Intangible assets		3,780,000

Liabilities assumed:
Accrued expenses		(408,825	)
Deferred tax liability		(661,658	)
Deferred revenue		(79,375	)

Goodwill	$	6,857,790

Business Acquisition, Pro Forma Information [Table Text Block]

	2021			2020
	Unaudited			Unaudited
Revenue	$	2,429,786		$	1,815,560
Net loss attributable to common shareholders	$	(18,878,432	)	$	(26,946,564	)

Note 4 - Stockholders' Equity, Stock Options and Warrants - Stock Offerings (Details) - USD ($)

12 Months Ended

Dec. 31, 2021

Dec. 31, 2020

Investor Warrants [Member]

$ 0

$ 5,057,919

Warrants issued, exercise price (in dollars per share)

$ 0.86

January 12, 2021 Registered Direct Offering [Member]

Shares issued, price per share (in dollars per share)

3,650,840

^[1]

$ 0.842

$ 3,074,007

$ 2,731,767

Shares issued, price per share (in dollars per share)

3,650,840

^[1]

$ 0.842

January 12, 2021 Registered Direct Offering [Member] | Investor Warrants [Member]

Warrants issued, exercise price (in dollars per share)

1,825,420

$ 0.80

January 12, 2021 Registered Direct Offering [Member] | Placement Agent Warrants [Member]

Warrants issued, exercise price (in dollars per share)

273,813

$ 1.0525

January 21, 2021 Registered Direct Offering [Member]

Shares issued, price per share (in dollars per share)

2,200,000

^[1]

$ 1.00

$ 2,200,000

$ 1,932,050

Shares issued, price per share (in dollars per share)

2,200,000

^[1]

$ 1.00

January 21, 2021 Registered Direct Offering [Member] | Investor Warrants [Member]

Warrants issued, exercise price (in dollars per share)

1,100,000

$ 1.00

January 21, 2021 Registered Direct Offering [Member] | Placement Agent Warrants [Member]

Warrants issued, exercise price (in dollars per share)

165,000

$ 1.25

January 26, 2021 Registered Direct Offering [Member]

Shares issued, price per share (in dollars per share)

3,414,970

^[1]

$ 1.20

$ 4,097,964

$ 3,668,687

Shares issued, price per share (in dollars per share)

3,414,970

^[1]

$ 1.20

January 26, 2021 Registered Direct Offering [Member] | Investor Warrants [Member]

Warrants issued, exercise price (in dollars per share)

1,707,485

$ 1.20

January 26, 2021 Registered Direct Offering [Member] | Placement Agent Warrants [Member]

Warrants issued, exercise price (in dollars per share)

256,123

$ 1.50

February 16, 2021 Registered Direct Offering [Member]

Shares issued, price per share (in dollars per share)

4,222,288

^[1]

$ 1.75

$ 7,389,004

$ 6,679,989

Shares issued, price per share (in dollars per share)

4,222,288

^[1]

$ 1.75

February 16, 2021 Registered Direct Offering [Member] | Investor Warrants [Member]

Warrants issued, exercise price (in dollars per share)

2,111,144

$ 2.00

February 16, 2021 Registered Direct Offering [Member] | Placement Agent Warrants [Member]

Warrants issued, exercise price (in dollars per share)

316,672

$ 2.1875

Febuary 23, 2021 Private Placement [Member]

Shares issued, price per share (in dollars per share)

9,043,766

^[1]

$ 1.95

$ 17,635,344

$ 16,064,739

Shares issued, price per share (in dollars per share)

9,043,766

^[1]

$ 1.95

Febuary 23, 2021 Private Placement [Member] | Investor Warrants [Member]

Warrants issued, exercise price (in dollars per share)

4,521,883

$ 2.00

Febuary 23, 2021 Private Placement [Member] | Placement Agent Warrants [Member]

Warrants issued, exercise price (in dollars per share)

678,282

$ 2.4375

June 16, 2021 Registered Direct Offering [Member]

Shares issued, price per share (in dollars per share)

15,520,911

$ 1.375

$ 21,341,252

$ 19,446,296

Shares issued, price per share (in dollars per share)

15,520,911

$ 1.375

June 16, 2021 Registered Direct Offering [Member] | Investor Warrants [Member]

Warrants issued, exercise price (in dollars per share)

15,520,911

$ 1.25

June 16, 2021 Registered Direct Offering [Member] | Placement Agent Warrants [Member]

Warrants issued, exercise price (in dollars per share)

1,164,068

$ 1.71875

Total Issuances [Member]

38,057,775

$ 55,737,571

$ 50,523,528

Total Issuances [Member] | Investor Warrants [Member]

38,057,775

Total Issuances [Member] | Placement Agent Warrants [Member]

26,786,843

2,853,958

[1]	Sale price includes one share and a warrant to purchase one-half share.

Note 4 - Stockholders' Equity, Stock Options and Warrants - Schedule of Listing of Stock Options and Warrants (Details)	Dec. 31, 2021 $ / shares shares
Shares, options (in shares) \| shares	1,062,871
Shares, warrants (in shares) \| shares	31,699,885
Minimum [Member]
Price, options (in dollars per share)	$ 0.72
Warrants issued, exercise price (in dollars per share)	0.80
Maximum [Member]
Price, options (in dollars per share)	5,962.50
Warrants issued, exercise price (in dollars per share)	$ 22.50
Warrants 2017 [Member]
Shares, warrants (in shares) \| shares	108,435
Warrants 2017 [Member] \| Minimum [Member]
Warrants issued, exercise price (in dollars per share)	$ 10.71
Warrants 2017 [Member] \| Maximum [Member]
Warrants issued, exercise price (in dollars per share)	$ 22.50
Warrants 2018 [Member]
Shares, warrants (in shares) \| shares	196,946
Warrants 2018 [Member] \| Minimum [Member]
Warrants issued, exercise price (in dollars per share)	$ 8.36
Warrants 2018 [Member] \| Maximum [Member]
Warrants issued, exercise price (in dollars per share)	$ 13.125
Warrants 2019 [Member]
Shares, warrants (in shares) \| shares	1,690,286
Warrants 2019 [Member] \| Minimum [Member]
Warrants issued, exercise price (in dollars per share)	$ 0.845
Warrants 2019 [Member] \| Maximum [Member]
Warrants issued, exercise price (in dollars per share)	$ 11.80
Warrants 2020 [Member]
Shares, warrants (in shares) \| shares	2,010,144
Warrants 2020 [Member] \| Minimum [Member]
Warrants issued, exercise price (in dollars per share)	$ 0.845
Warrants 2020 [Member] \| Maximum [Member]
Warrants issued, exercise price (in dollars per share)	$ 2.992
Warrants 2021 [Member]
Shares, warrants (in shares) \| shares	27,694,074
Warrants 2021 [Member] \| Minimum [Member]
Warrants issued, exercise price (in dollars per share)	$ 0.80
Warrants 2021 [Member] \| Maximum [Member]
Warrants issued, exercise price (in dollars per share)	$ 2.992
Stock Options 2012 [Member]
Shares, options (in shares) \| shares	114
Stock Options 2012 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 1.54
Stock Options 2012 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 1,500.00
Stock Options 2013 [Member]
Shares, options (in shares) \| shares	146
Stock Options 2013 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 1.54
Stock Options 2013 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 5,962.50
Stock Options 2014 [Member]
Shares, options (in shares) \| shares	84
Stock Options 2014 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 1.54
Stock Options 2014 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 3,468.75
Stock Options 2015 [Member]
Shares, options (in shares) \| shares	394
Stock Options 2015 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 1.54
Stock Options 2015 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 862.50
Stock Options 2016 [Member]
Shares, options (in shares) \| shares	9,174
Stock Options 2016 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 1.54
Stock Options 2016 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 42.50
Stock Options 2017 [Member]
Shares, options (in shares) \| shares	214,555
Stock Options 2017 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 1.54
Stock Options 2017 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 21.00
Stock Options 2018 [Member]
Shares, options (in shares) \| shares	78,325
Stock Options 2018 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 1.54
Stock Options 2018 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 13.50
Stock Options 2019 [Member]
Shares, options (in shares) \| shares	314,963
Stock Options 2019 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 1.54
Stock Options 2019 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 7.50
Stock Options 2020 [Member]
Shares, options (in shares) \| shares	303,199
Stock Options 2020 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 0.73
Stock Options 2020 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 3.48
Stock Options 2021 [Member]
Shares, options (in shares) \| shares	141,917
Stock Options 2021 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 0.72
Stock Options 2021 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 1.47

Note 7 - Derivatives (Details Textual)		3 Months Ended	12 Months Ended
Note 7 - Derivatives (Details Textual)	Sep. 28, 2018	Mar. 31, 2020 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Mar. 01, 2021 USD ($)	Jun. 30, 2020 USD ($)	May 08, 2020 USD ($)	Mar. 18, 2020 USD ($)	Feb. 05, 2020 USD ($)	Dec. 31, 2019 USD ($)	Sep. 30, 2019 USD ($)	Dec. 31, 2018 USD ($)
Embedded Derivative, Gain (Loss) on Embedded Derivative, Net, Total				$ 50,989
Derivative Liability, Total				0
Embedded Derivative, Fair Value of Embedded Derivative Liability			$ 129,480							$ 294,382		$ 50,989
Gain (Loss) on Derivative Instruments, Net, Pretax, Total			164,902	1,765,907
Promissory Note 2020 Conversion Feature, Tranche One [Member]
Embedded Derivative, Fair Value of Embedded Derivative Liability									$ 68,796
Promissory Note 2020 Conversion Feature, Tranche Two [Member]
Embedded Derivative, Fair Value of Embedded Derivative Liability									52,125
Promissory Note 2020 Conversion Feature, Tranche Three [Member]
Embedded Derivative, Fair Value of Embedded Derivative Liability									$ 20,542
Promissory Note 2020 Conversion Feature [Member]
Derivative Liability, Total			104,529	104,529	$ 0
Derivative, Gain (Loss) on Derivative, Net, Total				87,923
A, B and Agent Warrants [Member]
Derivative Liability, Total			41,336	33,654				$ 2,669,995
Derivative, Gain (Loss) on Derivative, Net, Total			(7,683)	69,479
A, B and Agent Warrants, Prior to Reclassification [Member]
Derivative, Gain (Loss) on Derivative, Net, Total		$ 700,910
Warrants and Agent Warrants In Connection With May 2020 Warrant [Member]
Derivative Liability, Total							$ 1,324,184
Embedded Derivative, Fair Value of Embedded Derivative Liability				1,324,184
Gain (Loss) on Derivative Instruments, Net, Pretax, Total				(460,065)
Agent Warrants Issued In connection With May 2020 Offering [Member]
Derivative Liability, Total			33,819	42,646
Derivative, Gain (Loss) on Derivative, Net, Total			(8,827)
Gain (Loss) on Derivative Instruments, Net, Pretax, Total				48,675
Warrants and Agent Warrants In Connection With June 2020 Warrant [Member]
Derivative Liability, Total						$ 1,749,721
Embedded Derivative, Fair Value of Embedded Derivative Liability				1,749,721
Gain (Loss) on Derivative Instruments, Net, Pretax, Total				834,520
Agent Warrants In Connection With June 2020 Warrant [Member]
Derivative Liability, Total			45,498	32,701
Derivative, Gain (Loss) on Derivative, Net, Total			12,797
Gain (Loss) on Derivative Instruments, Net, Pretax, Total				79,045
Promissory Note 2019 Conversion Feature [Member]
Derivative Liability, Total											$ 495,100
Promissory Note 2019 Conversion Feature Agent Warrants [Member]
Derivative Liability, Total				89,680	$ 0
Derivative, Gain (Loss) on Derivative, Net, Total			$ 89,680
Gain (Loss) on Derivative Instruments, Net, Pretax, Total				$ 405,420
Bridge Notes [Member] \| Convertible Promissory Note [Member]
Debt Instrument, Convertible, Threshold Trading Days	20

Note 8 - Loss Per Share (Tables)

12 Months Ended

Dec. 31, 2021

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

	Year Ended December 31,
	2021			2020
Numerator:
Net loss attributable to common shareholders per common share: basic and diluted calculation	$	(19,657,174	)	$	(26,438,684	)

Denominator:
Weighted average common shares outstanding-basic		54,876,044			11,950,154
Effect of diluted stock options, warrants and preferred stock (1)		-			-
Weighted average common shares outstanding-diluted		54,876,044			11,950,154
Loss per common share-basic and diluted	$	(0.36	)	$	(2.21	)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

	Year Ended December 31,
	2021		2020
Options		1,062,871		1,013,547
Warrants		31,699,885		7,353,376
Convertible debt		-		1,107,544
Preferred stock: Series B		79,246		79,246

Note 2 - zPredicta Acquisition - Fair Value of Assets Acquired and Liabilities Assumed (Details) - USD ($)	Nov. 24, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Goodwill, Ending Balance		$ 6,857,790	$ 2,813,792	$ 15,690,290
zPREDICTA [Member]
Payments to Acquire Businesses, Gross	$ 10,015,941
Cash	425,727
Accounts receivable	76,549
Prepaid expenses	25,733
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	3,780,000
Accrued expenses	(408,825)
Deferred tax liability	(661,658)
Deferred revenue	(79,375)
Goodwill, Ending Balance	$ 6,857,790

Note 13 - Segments - Segments (Details) - USD ($)	3 Months Ended	9 Months Ended		12 Months Ended
Note 13 - Segments - Segments (Details) - USD ($)	Dec. 31, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2021	Dec. 31, 2020
Revenue				$ 1,420,680	$ 1,252,272
Depreciation and Amortization				(1,340,301)	(1,024,848)
Impairment	$ (9,879,498)	$ (2,813,792)	$ (2,997,000)	(2,813,792)	(12,876,498)
Impairment expense – intangibles				(2,893,548)	0
Impairment expense – acquired software				(1,249,727)	0
Net loss				(19,657,174)	(25,884,397)
Assets	13,060,436			43,771,271	13,060,436
Impairment expense					(12,876,498)
Net loss				(19,657,174)	(25,884,397)
Corporate, Non-Segment [Member]
Revenue				4,119	0
Depreciation and Amortization				(16,319)	(41,362)
Net loss				(7,089,286)	(8,968,648)
Assets	211,510			28,536,489	211,510
Impairment expense					0
Net loss				(7,089,286)	(8,968,648)
Skyline [Member] \| Operating Segments [Member]
Revenue				1,169,811	1,185,214
Depreciation and Amortization				(30,002)	(38,310)
Net loss				(520,822)	(1,132,251)
Assets	1,191,439			906,977	1,191,439
Impairment expense					0
Net loss				(520,822)	(1,132,251)
Helomics Segment [Member] \| Operating Segments [Member]
Revenue				13,367	64,188
Depreciation and Amortization				(886,642)	(761,105)
Impairment				(2,813,792)
Impairment expense – intangibles				(2,893,548)
Impairment expense – acquired software				(1,249,727)
Net loss				(11,326,948)	(15,112,131)
Assets	9,773,902			1,802,792	9,773,902
Impairment expense					(12,876,498)
Net loss				(11,326,948)	(15,112,131)
Soluble [Member] \| Operating Segments [Member]
Revenue				233,293	2,870
Depreciation and Amortization				(366,713)	(184,071)
Net loss				(1,251,564)	(671,367)
Assets	$ 1,883,585			1,742,445	1,883,585
Impairment expense					0
Net loss				(1,251,564)	$ (671,367)
zPREDICTA [Member] \| Operating Segments [Member]
Revenue				90
Depreciation and Amortization				(40,625)
Net loss				531,446
Assets				10,782,568
Net loss				$ 531,446

Consolidated Statements of Stockholders' Equity - USD ($)	June 2020 Warrant [Member] Common Stock [Member]	June 2020 Warrant [Member] Additional Paid-in Capital [Member]	June 2020 Warrant [Member]	Warrants Issued Pursuant to 2020 Convertible Debt [Member] Additional Paid-in Capital [Member]	Warrants Issued Pursuant to 2020 Convertible Debt [Member]	Warrants Issued Pursuant to 2020 Convertible Debt 2 [Member] Additional Paid-in Capital [Member]	Warrants Issued Pursuant to 2020 Convertible Debt 2 [Member]	Prefunded Warrants [Member] Common Stock [Member]	Prefunded Warrants [Member] Additional Paid-in Capital [Member]	Prefunded Warrants [Member]	Preferred Stock [Member] Series B Convertible Preferred Stock [Member]	Preferred Stock [Member] Series D Convertible Preferred Stock [Member] Conversion of Series D Preferred Stock to Common Stock [Member]	Preferred Stock [Member] Series D Convertible Preferred Stock [Member]	Preferred Stock [Member] Series E Convertible Preferred Stock [Member] Series E Preferred Stock Conversions [Member]	Preferred Stock [Member] Series E Convertible Preferred Stock [Member]	Common Stock [Member] Registered Direct Offerings [Member]	Common Stock [Member] Private Placement [Member]	Common Stock [Member] June 2021 Offering [Member]	Common Stock [Member] May 2020 Offering [Member]	Common Stock [Member] Bridge Notes [Member]	Common Stock [Member] Series E Preferred Stock Conversions [Member]	Common Stock [Member] Conversion of Series D Preferred Stock to Common Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member] Registered Direct Offerings [Member]	Additional Paid-in Capital [Member] Private Placement [Member]	Additional Paid-in Capital [Member] June 2021 Offering [Member]	Additional Paid-in Capital [Member] May 2020 Offering [Member]	Additional Paid-in Capital [Member] Bridge Notes [Member]	Additional Paid-in Capital [Member] Series E Preferred Stock Conversions [Member]	Additional Paid-in Capital [Member] Conversion of Series D Preferred Stock to Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Registered Direct Offerings [Member]	Private Placement [Member]	June 2021 Offering [Member]	May 2020 Offering [Member]	Bridge Notes [Member]	Total
Balance (in shares) at Dec. 31, 2019											79,246		3,500,000		258								4,056,652
Balance at Dec. 31, 2019											$ 792		$ 35,000		$ 3								$ 40,567								$ 93,653,667	$ (82,498,711)						$ 11,231,318
Shares issued pursuant to CEO note conversion and accrued interest and exchange agreement (in shares)																							1,583,481
Shares issued pursuant to CEO note conversion and accrued interest and exchange agreement																							$ 15,835								2,307,043							2,322,878
Inducement shares issued pursuant to promissory note extension (in shares)																							30,000
Inducement shares issued pursuant to promissory note extension																							$ 300								40,950							41,250
Issuance of shares and prefunded warrants pursuant to March 2020 private placement (in shares)																							260,000
Issuance of shares and prefunded warrants pursuant to March 2020 private placement																							$ 2,600								455,223							457,823
Inducement shares issued pursuant to 2020 convertible debt and warrants (in shares)																							46,875
Inducement shares issued pursuant to 2020 convertible debt and warrants																							$ 468								119,532							120,000
Warrants issued pursuant to 2020 convertible debt				$ 116,951	$ 116,951	$ 62,373	$ 62,373
Shares issued pursuant to conversions (in shares)												(3,500,000)		(258)						170,000	1,398,607	350,004	2,212,359
Shares issued pursuant to conversions												$ (35,000)		$ (3)						$ 1,700	$ 13,986	$ 3,500	$ 22,124					$ 265,628	$ (13,983)	$ 31,500	1,006,230						$ 267,328	1,028,354
Issuance of shares from prefunded warrant exercises (in shares)	1,274,826							1,390,166															122,000
Issuance of shares from prefunded warrant exercises	$ 12,748	$ 1,682,237	$ 1,694,985					$ 13,902	$ (13,149)	$ 753													$ 1,220								190,930							192,150
Shares issued (in shares)																			1,396,826
Issuance of shares																			$ 13,968								$ 591,949									$ 605,917
Shares issued in connection with asset purchase agreement (in shares)																							1,079,719
Shares issued in connection with asset purchase agreement																							$ 10,797								1,661,970							1,672,767
Repricing and Reclassification of warrants issued pursuant to convertible debt		$ 803,455	$ 803,455																												1,865,953							1,865,953
Shares issued pursuant to Equity Line (in shares)																							4,231,073
Shares issued pursuant to Equity Line																							$ 42,311								4,849,037							4,891,348
Share issuance to consultant and other (in shares)																							202,199
Share issuance to consultant and other																							$ 2,022								428,184							430,206
Vesting expense and option repricing																															721,269							721,269
Net loss																																(25,884,397)						(25,884,397)
Balance (in shares) at Dec. 31, 2020											79,246		0		0								19,804,787
Balance at Dec. 31, 2020											$ 792		$ 0		$ 0								$ 198,048								110,826,949	(108,383,108)						2,642,681
Shares issued pursuant to CEO note conversion and accrued interest and exchange agreement (in shares)																							400,000
Shares issued pursuant to CEO note conversion and accrued interest and exchange agreement																							$ 4,000								(4,000)							0
Shares issued pursuant to conversions (in shares)																							1,107,544
Shares issued pursuant to conversions																							$ 11,075								502,936							514,011
Issuance of shares from prefunded warrant exercises (in shares)																							5,269,059
Issuance of shares from prefunded warrant exercises																							$ 52,702								4,461,169							4,513,871
Shares issued (in shares)																13,488,098	9,043,766	15,520,911
Issuance of shares																$ 134,881	$ 90,438	$ 155,209						$ 14,877,611	$ 15,974,301	$ 19,291,087							$ 15,012,492	$ 16,064,739	$ 19,446,296
Shares issued pursuant to Equity Line (in shares)																							647,504
Shares issued pursuant to Equity Line																							$ 6,475								669,115							675,590
Share issuance to consultant and other (in shares)																							174,954
Net loss																							$ 0								0	(19,657,174)						(19,657,174)
Balance (in shares) at Dec. 31, 2021											79,246												65,614,597
Balance at Dec. 31, 2021											$ 792												$ 656,146								167,649,028	(128,040,282)						40,265,684
Shares issued pursuant to agreement with former CEO related to accrued interest (in shares)																							100,401
Shares issued pursuant to agreement with former CEO related to accrued interest																							$ 1,004								142,569							143,573
Share issuance to consultant and other																							$ 1,750								203,443							205,193
Vesting expense and option repricing (in shares)																							57,573
Vesting expense and option repricing																							$ 564								$ 703,848							$ 704,412

Note 10 - Goodwill and Intangibles

12 Months Ended

Dec. 31, 2021

Intangible Assets Disclosure [Text Block]

NOTE 10 – Goodwill and Intangibles

Intangible Assets

Finite-lived intangible assets consist of patents and trademarks, licensing fees, developed technology, acquired software and customer relationships, and are amortized over their estimated useful life. Amortization expense was $374,328 and $313,709 in 2021 and 2020, respectively. Accumulated amortization is included in intangibles, net in the accompanying consolidated balance sheets. The Company reviews finite-lived identifiable intangible assets for impairment in accordance with ASC 360, Property, Plant and Equipment, whenever events or changes in circumstances indicate the carrying amount may not be recoverable. Events or changes in circumstances that indicate the carrying amount may not be recoverable include, but are not limited to, a significant change in the medical device marketplace and a significant adverse change in the business climate in which the Company operates.

As of December 31, 2021, there were $3,962,118 in net intangibles as compared to $3,398,101 in net intangibles as of December 31, 2020.

The components of intangible assets were as follows:

	December 31, 2021										December 31, 2020
	Gross Carrying Costs		Accumulated Amortization			Impairment			Net Carrying Amount		Gross Carrying Costs		Accumulated Amortization			Net Carrying Amount
Patents & Trademarks	$	453,314	$	(230,572	)	$	-		$	222,742	$	401,421	$	(211,110	)	$	190,311
Developed Technology		6,382,000		(432,733	)		(2,485,725	)		3,463,542		2,882,000		(252,175	)		2,629,825
Customer Relationships		645,000		(410,000	)		(37,083	)		197,917		445,000		(259,583	)		185,417
Tradename		478,000		(29,344	)		(370,740	)		77,917		398,000		(5,452	)		392,548
Total	$	7,958,314	$	(1,102,649	)	$	(2,893,548	)	$	3,962,118	$	4,126,421	$	(728,320	)	$	3,398,101

The following table outlines the estimated future amortization expense related to intangible assets held as of December 31, 2021:

Year ending December 31,	Expense
2022	$	411,609
2023		411,610
2024		411,610
2025		409,526
2026		391,610
Thereafter		1,926,153
Total	$	3,962,118

Impairment of Long-Lived Assets

The Company reviews long-lived assets, including property and equipment and intangible assets with estimable useful lives, for impairment whenever events or changes in circumstances indicate that the carrying amount of such an asset may not be recoverable.

The recoverability of an asset to be held and used is determined by comparing the carrying amount to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of the asset exceeded its estimated undiscounted future cash flows, the Company recorded an impairment charge in the amount by which the carrying amount of the asset exceeds its fair value, which is determined by either a quoted market price, if any, or a value determined by utilizing discounted cash flow techniques.

The Company prepared an undiscounted cash flow as of December 31, 2021 to evaluate long-lived assets based on a triggering event per ASC 360. The Company concluded that the undiscounted cash flows did not support the carrying values of its Helomics asset group at December 31, 2021. The Company determined the value of the intangibles and the software license acquired were fully impaired as of December 31, 2021 and recognized and impairment loss of $2,893,548 for its long-lived intangible assets and $1,249,727 for the acquired software. The Company concluded there was no impairment of its other finite lived tangible assets as of December 31, 2021. No impairment charges were incurred during 2020.

Goodwill

In accordance with ASC 350, Intangibles – Goodwill and Other, goodwill is calculated as the difference between the acquisition date fair value of the consideration transferred and the fair value of net assets acquired. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination. Goodwill is an indefinite-lived asset and is not amortized. Goodwill is tested for impairment annually at the reporting unit level, or whenever events or circumstances present an indication of impairment.

In the Helomics acquisition, the Company recorded goodwill of $23,790,290. The goodwill was recorded to the Helomics segment which represents a single reporting unit. As a part of the annual impairment testing as of December 31, 2019, the Company had the option to assess qualitative factors to determine if it was more likely than not that the carrying value of a reporting unit exceeded its estimated fair value. The Company believed a qualitative testing approach was not appropriate and, therefore, proceeded to the quantitative testing. When performing quantitative testing, the Company first estimated the fair value of the Helomics reporting unit using discounted cash flows. To determine fair values, the Company was required to make assumptions about a wide variety of internal and external factors. Significant assumptions used in the impairment analysis included financial projections of free cash flow (including significant assumptions about operations including the rate of future revenue growth, capital requirements, and income taxes), long-term growth rates for determining terminal value, and discount rates for the Helomics reporting unit. Comparative market multiples were also used to corroborate the results of the discounted cash flow test. These assumptions required significant judgment and actual results may differ from assumed and estimated amounts.

In testing goodwill for impairment as of September 30, 2020, the Company performed a quantitative impairment test, including computing the fair value of the Helomics reporting unit and comparing that value to its carrying value. Based upon the Company’s quantitative goodwill impairment test, the Company concluded that goodwill was impaired as of the testing date of September 30, 2020. Pursuant to ASU 2017-04, Simplifying the Test for Goodwill Impairment, the single step is to determine the estimated fair value of the reporting unit and compare it to the carrying value of the reporting unit, including goodwill. To the extent the carrying amount of goodwill exceeds the implied goodwill, the difference is the amount of the goodwill impairment. The quantitative review as of September 30, 2020 resulted in $2,997,000 of impairment expense related to goodwill.

When evaluating the fair value of Helomics reporting unit the Company used a discounted cash flow model and market comparisons. Key assumptions used to determine the estimated fair value included: (a) expected cash flow for the 20-year period following the testing date (including net revenues, costs of revenues, and operating expenses as well as estimated working capital needs and capital expenditures); (b) an estimated terminal value using a terminal year growth rate of 3.0% determined based on the growth prospects of the reporting unit; and (c) a discount rate of 25% based on management’s best estimate of the after-tax weighted average cost of capital. The discount rate included a Company specific risk premium of 10% for risks related to the term of the forecasts.

In testing goodwill for impairment as of December 31, 2020, the Company performed a quantitative impairment test, including computing the fair value of the Helomics reporting unit and comparing that value to its carrying value. Based upon the Company’s annual goodwill impairment test, the Company concluded that goodwill was impaired as of the testing date of December 31, 2020. The Company’s annual impairment test as of December 31, 2020 resulted in $9,879,498 of impairment expense related to goodwill. A decrease in the growth rate of 0.5% or an increase of 0.5% to the discount rate would reduce the fair value of Helomics reporting unit by approximately an additional $588,000 and $988,000, respectively. As of December 31, 2020, the cumulative impairment recorded was $20,976,498.

When evaluating the fair value of Helomics reporting unit the Company used a discounted cash flow model. Key assumptions used to determine the estimated fair value in 2020 included: (a) expected cash flow for the 10-year period following the testing date (including net revenues, costs of revenues, and operating expenses as well as estimated working capital needs and capital expenditures); (b) an estimated terminal value using a terminal year growth rate of 5.0% determined based on the growth prospects of the reporting unit; and (c) a discount rate of 14.0% based on management’s best estimate of the after-tax weighted average cost of capital. The discount rate included a Company specific risk premium of 1.0% for risks related to the term of the forecasts. The Company further used a probability weighting of various forecasts to address forecast risk.

During the third quarter of 2021, the Company concluded that potential impairment indicators were present and that an impairment assessment was warranted for goodwill. In testing goodwill for impairment as of September 30, 2021, the Company performed a quantitative impairment test, including computing the fair value of the Helomics reporting unit and comparing that value to its carrying value. Based upon the Company’s quantitative goodwill impairment test, the Company concluded that goodwill was fully impaired as of September 30, 2021.

The quantitative review as of September 30, 2021 resulted in $2,813,792 of impairment expense related to goodwill. As of September 30, 2021, the cumulative impairment recorded was $23,790,290.

When evaluating the fair value of Helomics reporting unit the Company used a discounted cash flow model and market comparisons. Key assumptions used to determine the estimated fair value included: (a) expected cash flow for the 10-year period following the testing date (including net revenues, costs of revenues, and operating expenses as well as estimated working capital needs and capital expenditures); (b) an estimated terminal value using a terminal year growth rate of 4.0% determined based on the growth prospects of the reporting unit; and (c) a discount rate of 15% based on management’s best estimate of the after-tax weighted average cost of capital. The Company further used a probability weighting of various forecasts to address forecast risk.

The following tables present changes in the carrying value of goodwill our consolidated balance sheet:

Goodwill balance at December 31, 2019	$	15,690,290
Impairment		(12,876,498	)
Goodwill balance at December 31, 2020	$	2,813,792
Impairment		(2,813,792	)
Acquisition of zPREDICTA		6,857,790
Goodwill balance at December 31, 2021	$	6,857,790

The majority of the inputs used in the discounted cash flow model are unobservable and thus are considered to be Level 3 inputs. The inputs for the market capitalization calculation are considered Level 1 inputs. The Company will continue to monitor its reporting units to determine whether events and circumstances warrant further interim impairment testing.

Note 4 - Stockholders' Equity, Stock Options and Warrants (Tables)

12 Months Ended

Dec. 31, 2021

Sales of Stock [Table Text Block]

Offering Closing Date	Shares		Sale Price per Share*		Investor Warrants		Exercise Price per Share – investor Warrants		Placement Agent Warrants		Exercise Price per Share – Placement Agent Warrants		Gross Proceeds of Offering		Net Proceeds of Offering
January 12, 2021 (registered direct)		3,650,840	$	0.842		1,825,420	$	0.80		273,813	$	1.0525	$	3,074,007	$	2,731,767
January 21, 2021 (registered direct)		2,200,000	$	1.00		1,100,000	$	1.00		165,000	$	1.25	$	2,200,000	$	1,932,050
January 26, 2021 (registered direct)		3,414,970	$	1.20		1,707,485	$	1.20		256,123	$	1.50	$	4,097,964	$	3,668,687
February 16, 2021 (registered direct)		4,222,288	$	1.75		2,111,144	$	2.00		316,672	$	2.1875	$	7,389,004	$	6,679,989
February 23, 2021 (private placement)		9,043,766	$	1.95		4,521,883	$	2.00		678,282	$	2.4375	$	17,635,344	$	16,064,739
June 16, 2021 (registered direct)		15,520,911	$	1.375		15,520,911	$	1.25		1,164,068	$	1.71875	$	21,341,252	$	19,446,296
Total		38,057,775				26,786,843				2,853,958			$	55,737,571	$	50,523,528

Share-based Payment Arrangement, Activity [Table Text Block]

	Stock Options					Warrants
	Number of Shares			Average Exercise Price		Number of Shares			Average Exercise Price

Outstanding at December 31, 2019		766,424		$	11.34		2,171,610		$	15.26

Issued		319,851			1.03		8,097,468			1.55
Forfeited		(72,728	)		10.58		(128,710	)		95.11
Exercised		-			-		(2,786,992	)		0.79

Outstanding at December 31, 2020		1,013,547		$	5.41		7,353,376		$	1.99

Issued		147,230			1.06		29,640,801			1.44
Forfeited		(92,593	)		8.64		-			-
Expired		-			-		(25,233	)		10.00
Exercised		(5,313	)		0.74		(5,269,059	)		0.86

Outstanding at December 31, 2021		1,062,871		$	4.83		31,699,885		$	1.66

Schedule of Share-based Compensation Shares Authorized Under Stock Option and Warrant Plans by Exercise Price Range [Table Text Block]

Range of Exercise Prices	Shares		Weighted Average Remaining Life
Options:
0.72 – 1.10		335,876		9.31
$1.15 – 1.64		356,673		8.36
$2.610 – 8.41		214,937		8.15
$10.10 – 5,962.50		155,385		5.99
Total		1,062,871

Warrants:
$0.80-1.72		21,468,599		3.31
$1.80 – 2.18		8,451,287		4.50
$2.25 – 10.00		1,555,778		3.37
$10.71 – 22.50		224,221		2.94
Total		31,699,885

Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]

Year	Shares		Price
2012		114		$1.54	–	$1,500.00
2013		146		1.54	–	5,962.50
2014		84		1.54	–	3,468.75
2015		394		1.54	–	862.50
2016		9,174		1.54	–	42.50
2017		214,555		1.54	–	21.00
2018		78,325		1.54	–	13.50
2019		314,963		1.54	–	7.50
2020		303,199		0.73	–	3.48
2021		141,917		0.72	–	1.47
Total		1,062,871		$0.72	–	$5,962.50

Year	Shares		Price
2017		108,435		$10.71	–	$22.50
2018		196,946		8.36	–	13.125
2019		1,690,286		0.845	–	11.80
2020		2,010,144		0.845	–	2.992
2021		27,694,074		0.80	–	2.992
Total		31,699,885		$0.80	–	$22.50

Note 4 - Stockholders' Equity, Stock Options and Warrants (Details Textual)											1 Months Ended				2 Months Ended	3 Months Ended	4 Months Ended	9 Months Ended	12 Months Ended
	Sep. 14, 2020 USD ($) $ / shares shares	Jul. 01, 2020 USD ($) shares	Jun. 12, 2020 shares	May 27, 2020 USD ($) shares	May 08, 2020 USD ($) $ / shares shares	Apr. 21, 2020 USD ($) $ / shares shares	Apr. 04, 2020 shares	Mar. 18, 2020 $ / shares shares	Oct. 29, 2019 $ / shares	Oct. 24, 2019 USD ($) shares	Jun. 30, 2020 USD ($) $ / shares shares	May 31, 2020 shares	Mar. 18, 2020 USD ($) $ / shares shares	Apr. 30, 2019 shares	Feb. 28, 2021 shares	Mar. 31, 2020 shares	Sep. 30, 2019 USD ($) shares	Sep. 30, 2021	Dec. 31, 2021 USD ($) $ / shares shares	Dec. 31, 2020 USD ($) $ / shares shares	Aug. 17, 2021 $ / shares shares	Aug. 10, 2021 shares	Jun. 30, 2021 shares	Sep. 23, 2020 $ / shares shares	Jan. 31, 2020 USD ($)	Jul. 15, 2019 USD ($)
Common Stock, Shares Authorized (in shares)																			200,000,000	100,000,000	200,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share) \| $ / shares	$ 0.01																		$ 0.01	$ 0.01	$ 0.01			$ 0.01
Sale of Stock, Agent Placement Fee, Percent of Gross Proceeds															7.50%
Sale of Stock, Management Fee, Percent of Gross Proceeds															1.00%
Proceeds from Warrant Exercises \| $																			$ 4,513,871	$ 1,935,855
Proceeds from Issuance or Sale of Equity, Net of Stock Issuance Costs \| $																			0	5,057,919
Debt Instrument, Face Amount \| $																			0	4,676,755
Fixed Assets Acquired for Notes Receivable and Common Stock \| $																			0	2,962,767
Fair Value Adjustment of Warrants \| $																			$ (164,902)	$ (1,765,907)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number (in shares)																			949,615	977,420
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price (in dollars per share) \| $ / shares																			$ 5.27	$ 5.29
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term (Year)																			8 years 1 month 20 days	8 years 9 months 3 days
Class of Warrant or Right Number of Warrants Vested and Exercisable (in shares)																			31,725,118	7,353,376
Share-based Payment Arrangement, Expense \| $																			$ 146,714	$ 780,269
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount \| $																			$ 70,324
Share-based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)																			19 years
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio									0.1
Other Capitalized Property Plant and Equipment [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment, Total \| $				$ 1,492,500
Asset Purchase Agreement with InventaBiotech and Its Subsidiaries, Soluble and BioDeth [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)				125,000
Fixed Assets Acquired for Notes Receivable and Common Stock \| $				$ 1,290,000
Asset Purchase Shares Issued Shares Escrow Deposit To Be Released Upon Six Months Anniversary Of Closing (in shares)				25,000
Asset Purchase Shares Issued, Shares Escrow Deposit To Be Released Upon Nine Months Anniversary Of Closing (in shares)				25,000
Business Acquisition, Right to Reclaim, Number of Shares (in shares)				10,000
Asset Purchase Agreement With Quantitative Medicine [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)		954,719
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable \| $		$ 1,470,267
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Held in Escrow (in shares)		477,359
Asset Purchase Agreement With Quantitative Medicine [Member] \| Carnegie Mellon University [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)		207,144
Conversion of Promissory Note Into Common Stock [Member]
Shares Issued, Price Per Share (in dollars per share) \| $ / shares						$ 1.43
DrSchwartz Notes [Member]
Debt Instrument, Face Amount \| $						$ 2,115,000																			$ 2,115,000	$ 1,920,000
DrSchwartz Notes [Member] \| Conversion of Promissory Note Into Common Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)						1,583,481
Conversion from Series D Preferred Stock to Common Stock [Member]
Conversion of Stock, Shares Converted (in shares)							3,500,000
Conversion of Stock, Shares Issued (in shares)							350,004
Conversion from Series E Preferred Stock to Common Stock [Member]
Conversion of Stock, Shares Converted (in shares)												207.7				50
Conversion of Stock, Shares Issued (in shares)			1,257,416													141,191
Conversion of Stock, Shares Issued, Percentage of Outstanding Shares			11.80%									0.05686%
Preferred Stock, Shares Outstanding, Ending Balance (in shares)			207.7
Series D Preferred Stock [Member]
Preferred Stock, Shares Issued, Total (in shares)														3,500,000
Convertible Preferred Stock, Conversion Rate														10
Series E Convertible Preferred Stock [Member]
Convertible Preferred Stock, Conversion Rate																	0.056857
Stock Issued During Period, Shares, Convertible Preferred Shares Issued (in shares)																	258
Preferred Stock, Beneficial Conversion Feature \| $																	$ 289,935
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares																			$ 22.50
Maximum [Member] \| Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)																			3 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)																			10 years
Equity Incentive Plan [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)																		3 years
Stock Incentive Plan 2012 [Member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)																						3,250,000	1,500,000
Investor Warrants [Member]
Stock Issued During Period, Shares, Warrant Exercises (in shares)																			5,269,059
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares																			$ 0.86
Proceeds from Warrant Exercises \| $																			$ 4,513,871
Placement Agent Warrants [Member]
Sale of Stock, Placement Agent, Warrants Assigned, Number of Securities Called by Warrants, Percent of Shares Sold															7.50%
Class of Warrant or Right, Exercise Price of Warrants or Rights, Percent of Stock Price															125.00%
Warrants issued with Private Placement [Member]
Warrants and Rights Outstanding, Term (Year)					5 years 6 months
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares					$ 1.45			$ 0.001					$ 0.001
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					1,396,826			1,390,166					1,390,166
Price of Warrant (in dollars per share) \| $ / shares								$ 2.12
Proceeds from Issuance or Sale of Equity, Total \| $					$ 2,200,001
Proceeds from Issuance or Sale of Equity, Net of Stock Issuance Costs \| $					$ 1,930,100
Shares Issued, Price Per Share (in dollars per share) \| $ / shares					$ 1.575
Series A Warrants [Member]
Warrants and Rights Outstanding, Term (Year)								5 years 6 months					5 years 6 months
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares								$ 1.88					$ 1.88
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)								1,650,166					1,650,166
Series B Warrants [Member]
Warrants and Rights Outstanding, Term (Year)								2 years					2 years
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares								$ 1.88					$ 1.88
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)								1,650,166					1,650,166
Prefunded Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares								$ 0.0001					$ 0.0001
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)								1,390,166					1,390,166
Price of Warrant (in dollars per share) \| $ / shares													$ 2.12
June 2020 Warrant [Member]
Warrants and Rights Outstanding, Term (Year)											5 years 6 months
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares											$ 1.80													$ 1.88
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)																								1,396,826
Class of Warrant or Right, Exercise Price of Warrants or Rights, Amended Price (in dollars per share) \| $ / shares																								$ 0.8457
Class Of Warrant Or Right, Purchase Price Per Warrant (in dollars per share) \| $ / shares											$ 0.125
Class of Warrant or Right, Percentage of Shares Issued Pursuant to Exercise of Existing Warrant											100.00%
Proceeds from Issuance and Exercise of Warrants \| $											$ 2,130,701
Proceeds from Issuance and Exercise of Warrants, Net \| $											$ 1,865,800
Warrant Issued in Connection With May 2020 Offering [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares											$ 1.45
Class of Warrant or Right Issued During Period (in shares)											1,396,826
Warrants Issued in Connection With Helomics Acquisition [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares	$ 0.845								$ 10.00
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	1,424,506
Fair Value Adjustment of Warrants \| $	$ 554,287
Registered Direct Offerings [Member]
Number of Warrants Issued to Each Investor, Per Two Shares of Stock Purchased (in shares)															1
Stock Issued During Period, Value, New Issues \| $																			15,012,492
Registered Direct Offerings [Member] \| Investor Warrants [Member]
Warrants and Rights Outstanding, Term (Year)															5 years 6 months
Registered Direct Offerings [Member] \| Placement Agent Warrants [Member]
Warrants and Rights Outstanding, Term (Year)															5 years
Private Placement [Member]
Common Stock, Par or Stated Value Per Share (in dollars per share) \| $ / shares					$ 0.01
Number of Warrants Issued to Each Investor, Per Two Shares of Stock Purchased (in shares)															1
Stock Issued During Period, Shares, New Issues (in shares)					1,396,826			260,000
Stock Issued During Period, Value, New Issues \| $																			16,064,739
Sale of Stock, Price Per Share (in dollars per share) \| $ / shares								$ 2.121					$ 2.121
Proceeds from Issuance or Sale of Equity, Total \| $													$ 3,498,612
Proceeds from Issuance or Sale of Equity, Net of Stock Issuance Costs \| $													$ 3,127,818
Private Placement [Member] \| Placement Agent Warrants [Member]
Warrants and Rights Outstanding, Term (Year)															5 years 6 months
June 2021 Offering [Member]
Stock Issued During Period, Value, New Issues \| $																			$ 19,446,296
June 2021 Offering [Member] \| Placement Agent Warrants [Member]
Warrants and Rights Outstanding, Term (Year)															3 years
Equity Line Purchase Agreement [Member]
Issuance or Sale of Equity, Can Be Raised \| $										$ 15,000,000
Stock Issued During Period, Shares, New Issues (in shares)										104,651									647,504	4,231,073
Stock Issued During Period, Value, New Issues \| $										$ 450,000									$ 675,590	$ 4,891,348
Sale of Stock, Remaining Available Balance \| $																			$ 9,113,829

Note 14 - Related Party Transactions

12 Months Ended

Dec. 31, 2021

NOTE 14 – RELATED PARTY TRANSACTIONS

The Audit Committee has the responsibility to review and approve all transactions to which a related party and the Company may be a party prior to their implementation, to assess whether such transactions meet applicable legal requirements.

One of the Company’s former directors, Richard L. Gabriel, is the Chief Operating Officer of GLG Pharma (“GLG”) and serves as a director of that firm. The Company and GLG have a partnership agreement for the purpose of bringing together their proprietary technologies to build out personalized medicine platform for the diagnosis and treatment of women’s cancer. There has been no revenue or expenses generated by this partnership to date.

Richard L. Gabriel was also contracted as the Chief Operating Officer for TumorGenesis. Through April 1, 2019, Mr. Gabriel received $12,000 per month pursuant to a renewable six-month contract. On May 1, 2019, Mr. Gabriel executed a one-year contract with renewable three-month periods to continue as the Chief Operating Officer for TumorGenesis, receiving $13,500 in monthly cash payments.

Effective May 1, 2021, Richard Gabriel resigned as a member of the Company’s Board of Directors. Mr. Gabriel’s resignation is in connection with his assuming a management position with the Company, and not due to any disagreements with the Company on any of our operations, policies or practices.

Note 1 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment, Useful Life (Details)

12 Months Ended

Dec. 31, 2021

Demo Equipment [Member]

Minimum [Member] | Office Equipment [Member]

3 years

Minimum [Member] | Leasehold Improvements [Member]

3 years

Minimum [Member] | Manufacturing Tooling [Member]

2 years

^[1]

Minimum [Member] | Laboratory Equipment [Member]

3 years

Maximum [Member] | Office Equipment [Member]

4 years

Maximum [Member] | Leasehold Improvements [Member]

10 years

Maximum [Member] | Manufacturing Tooling [Member]

5 years

^[1]

Maximum [Member] | Laboratory Equipment [Member]

7 years

10 years

[1]	Leasehold improvements are amortized over the shorter of the useful life or the remaining lease term.

Note 6 - Notes Payable

12 Months Ended

Dec. 31, 2021

Debt Disclosure [Text Block]

NOTE 6 – NOTES PAYABLE

The balances of notes payable were as follows:

	Due Date	December 31, 2021		December 31, 2020
2018 Investor loan	March 31, 2021	$	-	$	1,721,776
Promissory note 2019	March 27, 2021		-		1,490,833
Promissory note 2020	March 31, 2021		-		1,464,146
Total Notes Payable, gross			-		4,676,755
Less: Unamortized discount			-		244,830
Total Notes Payable, net		$	-	$	4,431,925

Secured Notes and Repayment in Full

In September 2018, the Company issued convertible secured promissory notes to two private investors in the original principal amount of an aggregate $2,297,727 (together, the “2018 Investor Note”) in exchange for cash proceeds of $2,000,000. As additional consideration for the 2018 Investor Note, the Company issued an aggregate 65,000 shares of its common stock as inducement shares plus warrants to acquire up to an aggregate 107,178 shares of common stock at an exercise price of $11.55 per share. Pursuant to a security agreement between the Company and the investors, the Company granted to the investors a security interest in its assets to secure repayment of the note. The 2018 Investor Note accrued interest at a rate of 8% per annum. In February 2019, the Company entered into a forbearance agreement with the 2018 Investor Note investors pursuant to which, among other things, the investors agreed to forbear on their rights to accelerate the 2018 Investor Note based on an event of default and a claimed event of default. In connection with such forbearance, an additional $344,659 in principal and an additional 16,667 common shares were issued to the investors. In September 2019, the 2018 Investor Note of one investor was paid in full. On March 19, 2020, the Company and the L2 Capital, LLC (“L2”) agreed to extend the note maturity to June 28, 2020. The Company and L2 further agreed to extend the due date to July 15, 2020 and then in July 2020 agreed to extend to September 30, 2020. Effective September 30, 2020, L2 and the Company agreed to extend to March 31, 2021.

Each investor received the right to convert all or any part of its portion of the 2018 Investor Note into shares of the Company’s common stock at a discounted price, subject to certain limitations. During the year ended December 31, 2020, L2 converted $267,328 of the principal balance, and received 170,000 shares of the Company’s common stock.

During September 2019, the Company issued a secured promissory note with a principal amount of $847,500 (the “2019 Investor Note”) to Oasis Capital, LLC (“Oasis”), an affiliate of L2, in exchange for cash proceeds of $700,000. As additional consideration for the loan, the Company issued an aggregate 8,857 shares of its common stock to Oasis plus warrants to acquire up to 68,237 shares of the Company’s common stock at an exercise price of $6.21 per share. The warrants are exercisable beginning on the sixth month anniversary of the effective date through the fifth-year anniversary thereof. The 2019 Investor Note accrued interest at a rate of 8% per annum. On March 19, 2020, the Company entered into an agreement to extend the due date the 2019 Investor Note from March 2020 to June 27, 2020. The Company increased the principal amount due on the 2019 Investor Note by $300,000 and issued 30,000 shares of its common stock as consideration for the extension. The change in value resulting from the extension exceeded 10% and as a result the extension was accounted for as an extinguishment under ASC 470, Debt. During the first quarter of 2020, the Company incurred a $300,000 loss on debt extinguishment related to the extension of the note. The Company and Oasis further agreed to extend the due date of the note to July 15, 2020 and then agreed to extend to September 30, 2020. The change in value resulting from the extension to September 30, 2020 exceeded 10% and as a result the extension was accounted for as an extinguishment under ASC 470, Debt. During the third quarter of 2020, the Company incurred a $345,000 loss on debt extinguishment related to the extension of the 2019 Investor Note to September 30, 2020. Effective September 30, 2020, Oasis and the Company agreed to further extend the maturity date of the 2019 Investor Note to March 31,2021. The change in value resulting from the extension to March 31, 2021 exceeded 10% and as a result the extension was accounted for as an extinguishment under ASC 470, Debt. During the third quarter of 2020, the Company incurred a $690,000 loss on debt extinguishment related to the extension of the note to March 31, 2021. Further, the parties agreed that the note shall be convertible into shares of the Company’s common stock, at a conversion price equal to the lesser of (i) $1.00 and (ii) 70% of the lowest VWAP (as defined in the note) of the Company’s common stock during the twenty (20) Trading Day (as defined) period ending on either (i) the last complete Trading Day prior to the conversion date or (ii) the conversion date, as determined by the holder in its sole discretion upon such conversion (subject to adjustment). During the fourth quarter of 2020, Oasis converted $525,000 in outstanding principal of the 2019 Investor Note in exchange for 1,136,448 shares of the Company’s common stock. No payment penalties were paid in relation to payments on this promissory note during the year ended December 31, 2020 and $320,542 in payment penalties were accrued but not paid as of December 31, 2020. As of December 31, 2020, the remaining balance on the promissory note was $1,490,833 with $244,830 unamortized discount.

On February 5, 2020, the Company issued a secured promissory note with a principal amount of $1,450,000 (the “2020 Investor Note”) to Oasis. Net proceeds of $400,000 were received for each of the first, second, and third tranches on February 5, 2020, March 5, 2020, and April 5, 2020, respectively. The Company granted to Oasis a security interest in its assets to secure repayment of the note. The 2020 Investor Note accrued interest at a rate of 8% per annum. Subject to certain limitations, the outstanding principal amount of the note and interest thereon were convertible at the election of the investor into shares of the Company’s common stock at a conversion price equal to $2.589. The conversion price was amended effective September 30, 2020 to a variable price equal to 70% of the lowest VWAP (as defined in the note) of Company’s common stock during the twenty (20) Trading Day (as defined in the note) period ending on either (i) the last complete Trading Day prior to the conversion date or (ii) the conversion date, as determined by the holder in its sole discretion upon such conversion (subject to adjustment). The note contains a conversion feature and a put which were determined to be derivatives and are discussed further below. Effective July 15, 2020, the Company and Oasis agreed to amend the maturity date of the note to September 30, 2020. The change in value resulting from the amendment to maturity to September 30, 2020 exceeded 10% and as a result the amendment was accounted for as an extinguishment under ASC 470, Debt. During the third quarter of 2020, the Company incurred a $172,500 loss on debt extinguishment related to the amendment of the note to September 30, 2020. Effective September 30, 2020, the investor and the Company agreed to further extend the maturity date of the 2020 Investor Note to March 31, 2021. The change in value resulting from the extension to March 31, 2021 exceeded 10% and as a result the extension was accounted for as an extinguishment under ASC 470, Debt. During the third quarter of 2020, the Company incurred a $345,000 loss on debt extinguishment related to the extension of the note to March 31, 2021. As additional consideration, the Company issued to Oasis warrants to purchase 94,631, 92,700 and 92,700 shares of the Company’s common stock at the closing of the first, second and third tranches, respectively. The warrants are exercisable beginning on the sixth month anniversary of the issuance date at an exercise price equal $2.992 per share. The Company also issued 46,875 shares of its common stock to Oasis at the closing of the first tranche. During the fourth quarter of 2020, Oasis converted $503,354 in outstanding principal in exchange for 1,075,911 shares of the Company’s common stock. No payment penalties were paid in relation to payments on this promissory note during the year ended December 31, 2020 and $314,011 in payment penalties were accrued but not paid as of December 31, 2020. As of December 31, 2020, the outstanding balance on the promissory note was $1,464,146 with no remaining unamortized discount.

On March 1, 2021, the Company used $5,906,802 of the proceeds of the private placement on February 23, 2021, described below under “2021 Offerings”, to repay in full the outstanding principal and interest and applicable premium amounts under the 2018 Investor Note, the 2019 Investor Note and the 2020 Investor Note.

Dr. Schwartz Notes

In November 2018, Dr. Schwartz made a loan to the Company with a principal balance of $370,000. As of December 31, 2018, one promissory note was held with a principal balance of $370,000 and an unamortized discount of $63,028. From November 30, 2018 through July 15, 2019, Dr. Schwartz made numerous loans to the Company in the total amount of $1,920,000 under two promissory notes. As consideration for these amounts, Dr. Schwartz received promissory notes and warrants to purchase 22,129 shares of the Company’s common stock at $8.36 per share. Further, beginning on February 1, 2019 and the first day of each calendar month thereafter while the note remained outstanding, a number of additional warrants were issued. Beginning in October 2019, the Company and Dr Schwartz began to renegotiate the note. Due to the negotiations, the Company did not issue any additional warrants because they would be cancelled under the new deal.

During January 2020, the Company entered into an exchange agreement with Dr. Schwartz. Under the exchange agreement, the two outstanding notes were cancelled and in exchange a new promissory note in the amount of $2,115,000 bearing 12% interest per annum and maturing on September 30, 2020 was issued. In addition to the promissory note, Dr. Schwartz received 50,000 shares of the Company’s common stock. All warrants issued under the prior promissory notes were cancelled under the exchange agreement; no rights and obligations remain under the cancelled notes. The Company determined that the exchange agreement had, in substance, occurred at December 31, 2019.

Effective as of April 21, 2020, the Company and Carl Schwartz, entered into an exchange agreement relating to a promissory note of the Company dated January 31, 2020 issued by the Company in the principal amount of $2,115,000. The note bore twelve percent (12%) interest per annum and had a maturity date of September 30, 2020. The accrued interest on the note through April 21, 2020 was $77,878, resulting in a total balance of $2,192,878 in principal and accrued interest on the Note as of such date. Dr. Schwartz and the Company agreed to exchange the note for newly issued shares of common stock of the Company at market value. Pursuant to the exchange agreement, Dr. Schwartz was issued 1,583,481 shares of newly issued common stock at an exchange rate of $1.43 per share, equal to the closing price of the common stock on April 21, 2020. Dr. Schwartz agreed (1) not to sell or otherwise transfer 766,740 shares for three months after the date of the exchange agreement, and (2) not to sell or otherwise transfer the remaining 766,741 shares for six months after the date of the exchange agreement. In 2021, the Company determined that due to a calculation error, the balance of the 2020 Schwartz Note should have been higher by $143,573 at the time of the exchange agreement, and on February 24, 2021, the Company issued an additional 100,401 shares to Dr. Schwartz.

Short Term Borrowings

The Company entered into short-term borrowings with an investor. The maturity date of the notes is six months after the dates of issuance with interest rates of 8% payable at maturity. Repayment of such notes is subject to a premium. During year ended December 31, 2020, the Company issued short term notes for a total of $1,098,684 for cash proceeds of $1,020,000 and repaid $1,459,973 of principal using a portion of proceeds from the equity financing facility. Payment penalties of $247,327 were paid in relation to payments on these short-term borrowings during the year ended December 31, 2020. There were no amounts outstanding under the short-term borrowings as of December 31, 2020.

April 2020 Paycheck Protection Program

On April 20, 2020, the Company entered into a promissory note with Park State Bank, which provides for an unsecured loan of $541,867 pursuant to the Paycheck Protection Program (the “PPP”) under the Coronavirus Aid, Relief, and Economic Security Act and applicable regulations (the “CARES Act”). The promissory note has a term of 2 years with a 1% per annum interest rate. Payments are deferred for 6 months from the date of the promissory note and the Company can apply for forgiveness of all or a portion of the promissory note after 60 days for covered use of funds.

Pursuant to the terms of the PPP, the promissory note, or a portion thereof, may be forgiven if proceeds are used for qualifying expenses as described in the CARES Act, such as payroll costs, costs used to continue group health care benefits, mortgage interest payments, rent and utilities. The Company has used all proceeds for qualifying expenses. The Company received forgiveness for the loan under the Paycheck Protection Program and recognized a gain in other income for the full amount of the loan during the fourth quarter of 2020.

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI http://asc.fasb.org/topic&trid=2208564

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Basis of Accounting, Policy [Policy Text Block]

Note 16 - Subsequent Events (Details Textual) - Equity Line Purchase Agreement [Member] - USD ($)		3 Months Ended	12 Months Ended
	Oct. 24, 2019	Mar. 28, 2022	Dec. 31, 2021	Dec. 31, 2020
Stock Issued During Period, Shares, New Issues (in shares)	104,651		647,504	4,231,073
Stock Issued During Period, Value, New Issues	$ 450,000		$ 675,590	$ 4,891,348
Subsequent Event [Member]
Stock Issued During Period, Shares, New Issues (in shares)		120,000
Stock Issued During Period, Value, New Issues		$ 86,885

Note 11 - Leases - Lease Information (Details)	Dec. 31, 2021	Dec. 31, 2020
Weighted average remaining lease term – operating leases in years (Year)	1 year 8 months 8 days	2 years 3 months 29 days
Weighted average discount rate – operating leases	8.00%	8.00%

Note 9 - Income Taxes (Details Textual) - USD ($)	12 Months Ended
Note 9 - Income Taxes (Details Textual) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Income Tax Expense (Benefit), Total	$ (661,658)	$ 0
Valuation Allowance Percentage	100.00%
Unrecognized Tax Benefits, Ending Balance	$ 0
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total	0	0
Domestic Tax Authority [Member]
Operating Loss Carryforwards, Total	308,990,822	297,735,754
Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration	259,490,005	261,455,216
Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration	49,500,817	36,280,538
Operating Loss Carryforwards, Valuation Allowance, Total	62,034,750	59,913,739
State and Local Jurisdiction [Member]
Operating Loss Carryforwards, Total	227,277,399	222,290,524
Operating Loss Carryforwards, Valuation Allowance, Total	$ 23,145,374	22,191,346
Foreign Tax Authority [Member]
Operating Loss Carryforwards, Valuation Allowance, Total		$ 0

Note 2 - zPredicta Acquisition (Details Textual) - USD ($)		12 Months Ended
	Nov. 24, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Goodwill, Ending Balance		$ 6,857,790	$ 2,813,792	$ 15,690,290
zPREDICTA [Member]
Payments to Acquire Businesses, Gross	$ 10,015,941
Business Combination, Acquisition Related Costs		$ 895,297
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	3,780,000
Goodwill, Ending Balance	6,857,790
zPREDICTA [Member] \| Trade Names [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	80,000
Finite-Lived Intangible Asset, Useful Life (Year)		4 years
zPREDICTA [Member] \| Developed Technology [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	3,500,000
Finite-Lived Intangible Asset, Useful Life (Year)		10 years
zPREDICTA [Member] \| Customer Relationships [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	$ 200,000
Finite-Lived Intangible Asset, Useful Life (Year)		10 years

Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2021

Accounting Policies [Abstract]

Nature of Operations and Continuance of Operations

The Company operates in four primary business areas: first, application of artificial intelligence (“AI”) in our precision medicine business, to provide AI-driven predictive models of tumor drug response to improve clinical outcomes for patients and to assist pharmaceutical, diagnostic, and biotech industries in the development of new personalized drugs and diagnostics primarily through its wholly owned subsidiary Helomics Holding Corporation (“Helomics”); second, tumor-specific in vitro models for oncology drug discovery and research through its newly acquired wholly-owned subsidiary, zPREDICTA; third, contract services and research focused on solubility improvements, stability studies, and protein production, primarily with our Soluble Biotech subsidiary, and; fourth, production of the United States Food and Drug Administration (“FDA”)-cleared STREAMWAY System for automated, direct-to-drain medical fluid waste disposal and associated products through its incorporated division Skyline.

The Company had cash and cash equivalents of $28,202,615 as of December 31, 2021. As of December 31, 2021, there was no outstanding debt. The Company believes that its existing capital resources will be sufficient to support its operating plan for the next twelve months and beyond. However, the Company may also seek to raise additional capital to support its growth through additional debt, equity or other alternatives or a combination thereof. The Company currently expects to use cash on hand to fund capital and equipment investments, research and development, potential acquisitions and its operations, and expects such sources to be sufficient to fund its requirements over that time.

Effect of Covid-19 Pandemic [Policy Text Block]

Coronavirus Outbreak

The current COVID-19 worldwide pandemic has presented substantial public health challenges. In response to the crisis, emergency measures have been imposed by governments worldwide, including mandatory social distancing and the shutdown of non-essential businesses. These measures have adversely impacted the global economy, disrupted global supply chains and created significant volatility and disruption of financial markets, and our business and operations have been and will likely continue to be materially and adversely affected. For example, our contract manufacturer for the STREAMWAY® System has been forced to change locations, thereby delaying our order fulfillment for parts. We have also reduced on-site staff at several of our facilities, resulting in delayed production, less efficiency, and our sales staff is unable to visit with hospital administrators who are our customers and potential customers. In addition, COVID-19 has impacted the Company’s capital and financial resources, including our overall liquidity position and outlook. For instance, our accounts receivable has slowed while our suppliers continue to ask for pre-delivery deposits. Ultimately, the extent of the impact of the COVID-19 pandemic on our future operational and financial performance will depend on, among other matters, the duration and intensity of the pandemic; the level of success of global vaccination efforts; governmental and private sector responses to the pandemic and the impact of such responses on us; and the impact of the pandemic on our employees, customers, suppliers, operations and sales, all of which are uncertain and cannot be predicted. These factors may remain prevalent for a significant period of time even after the pandemic subsides, including due to a continued or prolonged recession in the U.S. or other major economies. Even in areas where "stay-at-home" restrictions, masking and social distancing measures have been lifted and the number of COVID-19 cases have declined, some jurisdictions may re-impose these measures as and if variant strains emerge or cases rise. The impacts of the COVID-19 pandemic, as with any adverse public health developments, could have a material adverse effect on our business, results of operations, liquidity or financial condition and heighten or exacerbate risks described in this Annual Report on Form 10-K.

New Accounting Pronouncements, Policy [Policy Text Block]

Recently Adopted Accounting Standards

The Company considers the applicability and impact of all Accounting Standards Updates (“ASUs”) issued by the Financial Accounting Standards Board (the “FASB”). Recently issued ASUs not listed below either were assessed and determined to be not applicable or are currently expected to have no impact on the condensed consolidated financial statements of the Company.

In June 2016, the FASB issued ASU 2016-13, “Financial Instruments – Credit Losses.” This ASU added a new impairment model (known as the current expected credit loss (“CECL”) model) that is based on expected losses rather than incurred losses. Under the new guidance, an entity recognizes as an allowance its estimate of expected credit losses. The CECL model applies to most debt instruments, trade receivables, lease receivables, financial guarantee contracts, and other loan commitments. The CECL model does not have a minimum threshold for recognition of impairment losses and entities will need to measure expected credit losses on assets that have a low risk of loss. As a smaller reporting company pursuant to Rule 12b-2 of the Securities Exchange Act of 1934, as amended, these changes become effective for the Company on January 1, 2023. Management is currently evaluating the potential impact of these changes on the consolidated financial statements of the Company.

Use of Estimates, Policy [Policy Text Block]

Accounting Policies and Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and disclosure of contingent assets and liabilities at the date of the financial statements and during the reporting period. Actual results could materially differ from those estimates.

Reclassification, Comparability Adjustment [Policy Text Block]

Reclassifications

Certain reclassifications have been made to the prior years’ financial statements to conform to the current year presentation. The reclassifications had no effect on previously reported results of operations, cash flows or stockholders’ equity.

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash and cash equivalents

The Company considers all highly liquid instruments with maturities when purchased of three months or less to be cash equivalents. The Company places its cash with high quality financial institutions and believes its risk of loss is limited to amounts in excess of that which is insured by the Federal Deposit Insurance Corporation.

Receivable [Policy Text Block]

Receivables

Receivables are reported at the amount the Company expects to collect on balances outstanding. The Company provides for probable uncollectible amounts through charges to earnings and credits to the valuation allowance based on management’s assessment of the current status of individual accounts.

Amounts recorded in accounts receivable on the consolidated balance sheet include amounts billed and currently due from customers. The amounts due are stated at their net estimated realizable value. An allowance for doubtful accounts is maintained to provide for the estimated amount of receivables that will not be collected. The Company reviews customers’ credit history before extending unsecured credit and establishes an allowance for uncollectible accounts based upon factors surrounding the credit risk of specific customers, historical trends and other information. Invoices are generally due 30 days after presentation. Accounts receivable over 30 days is generally considered past due. The Company does not accrue interest on past due accounts receivables. Receivables are written off once all collection attempts have failed and are based on individual credit evaluation and specific circumstances of the customer. The allowance for doubtful accounts balance was $0 as of both December 31, 2021 and 2020.

Fair Value Measurement, Policy [Policy Text Block]

Fair Value Measurements

As outlined in Accounting Standards Codification (“ASC”) 820, Fair Value Measurement, fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting standards ASC 820 establishes a three-level fair value hierarchy that prioritizes information used in developing assumptions when pricing an asset or liability as follows:

Level 1 – Observable inputs such as quoted prices in active markets;

Level 2 – Inputs other than quoted prices in active markets, that are observable either directly or indirectly; and

Level 3 – Unobservable inputs where there is little or no market data, which requires the reporting entity to develop its own assumptions.

The Company uses observable market data, when available, in making fair value measurements. Fair value measurements are classified according to the lowest level input that is significant to the valuation.

The fair value of the Company’s investment securities, which consist of cash and cash equivalents, was determined based on Level 1 inputs. The fair value of the Company’s derivative liabilities and debt were determined based on Level 3 inputs. The Company generally uses Black Scholes method for determining the fair value of warrants classified as liabilities on a recurring basis. In addition, the Company uses the Monte Carlo method and other acceptable valuation methodologies when valuing the conversion feature and other embedded features classified as derivatives on a recurring basis. See Note 7 – Derivatives. When performing quantitative testing related to goodwill impairment analysis, the Company estimates the fair values of its reporting units using discounted cash flows. To determine fair values, the Company is required to make assumptions about a wide variety of internal and external factors. Significant assumptions used in the impairment analysis include financial projections of free cash flow (including significant assumptions about operations including the rate of future revenue growth, capital requirements, and income taxes), long-term growth rates for determining terminal value and discount rates. The majority of the inputs used in the discounted cash flow model are unobservable and thus are considered to be Level 3 inputs. See Note 10 – Goodwill and Intangibles.

The acquisition of zPREDICTA was accounted for as a business combination using the acquisition method of accounting. This method requires, among other things, that assets acquired and liabilities assumed be recognized at fair value as of the acquisition date. The fair value for the assets acquired and the liabilities assumed are based on information knowable and determined by management as of the acquisition date. The majority of the inputs used in the discounted cash flow model, the relief-from-royalty method under the income approach, the distributor method under the income approach and the multi-period excess earnings method under the income approach, each are unobservable and thus are considered to be Level 3 inputs. See Note 2 – zPREDICTA Acquisition.

Inventory, Policy [Policy Text Block]

Inventories

Inventories are stated at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis.

Property, Plant and Equipment, Policy [Policy Text Block]

Fixed Assets

Fixed assets are stated at cost less accumulated depreciation. Depreciation of fixed assets is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows:

	Years
Computers, software and office equipment	3	-	10
Leasehold improvements (1)	2	-	5
Manufacturing tooling	3	-	7
Laboratory equipment	4	-	10
Demo equipment		3

(1)

Leasehold improvements are amortized over the shorter of the useful life or the remaining lease term.

Upon retirement or sale of fixed assets, the cost and related accumulated depreciation or amortization are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations expense as incurred.

Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]

Long-lived Assets

Finite-lived intangible assets consist of patents and trademarks, licensing fees, developed technology, acquired software and customer relationships, and are amortized over their estimated useful life. Accumulated amortization is included in intangibles, net in the accompanying consolidated balance sheets.

The Company reviews finite-lived identifiable intangible assets for impairment in accordance with ASC 360, Property, Plant and Equipment, whenever events or changes in circumstances indicate the carrying amount may not be recoverable. Events or changes in circumstances that indicate the carrying amount may not be recoverable include, but are not limited to, a significant change in the medical device marketplace and a significant adverse change in the business climate in which the Company operates.

The Company also prepared an undiscounted cash flow as of December 31, 2020 to evaluate long-lived assets based on a triggering event at that time. The Company concluded that the undiscounted cash flows of the long-lived assets exceeded the carrying values. The Company concluded there was no impairment of its finite lived assets as of December 31, 2020.

Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]

Goodwill

In accordance with ASC 350, Intangibles – Goodwill and Other, goodwill is calculated as the difference between the acquisition date fair value of the consideration transferred and the fair value of net assets acquired. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination. Goodwill is not amortized but is tested on an annual basis for impairment at the reporting unit level as of December 31, or whenever events or changes in circumstances indicate that the carrying amount may not be fully recoverable.

To determine whether goodwill is impaired, annually or more frequently if needed, the Company performs a multi-step impairment test. The Company first has the option to assess qualitative factors to determine if it is more likely than not that the carrying value of a reporting unit exceeds its estimated fair value. The Company may also elect to skip the qualitative testing and proceed directly to the quantitative testing. When performing quantitative testing, the Company first estimates the fair values of its reporting units using discounted cash flows. To determine fair values, the Company is required to make assumptions about a wide variety of internal and external factors. Significant assumptions used in the impairment analysis include financial projections of free cash flow (including significant assumptions about operations including the rate of future revenue growth, capital requirements, and income taxes), long-term growth rates for determining terminal value and discount rates. Comparative market multiples are used to corroborate the results of the discounted cash flow test. These assumptions require significant judgement. Pursuant to ASU 2017-04, Simplifying the Test for Goodwill Impairment, the single step is to determine the estimated fair value of the reporting unit and compare it to the carrying value of the reporting unit, including goodwill. To the extent the carrying amount of goodwill exceeds the implied goodwill, the difference is the amount of the goodwill impairment. The Company also completes a reconciliation between the implied equity valuation prepared and the Company’s market capitalization. The majority of the inputs used in the discounted cash flow model are unobservable and thus are considered to be Level 3 inputs. The inputs for the market capitalization calculation are considered Level 1 inputs. See Note 3 – Intangible Assets and Goodwill.

Lessee, Leases [Policy Text Block]

Leases – At inception of a contract a determination is made whether an arrangement meets the definition of a lease. A contract contains a lease if there is an identified asset and the Company has the right to control the asset. Operating leases are recorded as right-of-use (“ROU”) assets with corresponding current and noncurrent operating lease liabilities on our consolidated balance sheets. Financing leases are included within fixed assets with corresponding current liability within other current liabilities and noncurrent liability within other long-term liabilities on our consolidated balance sheets.

ROU assets represent our right to use an underlying asset for the duration of the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Recognition on the commencement date is based on the present value of lease payments over the lease term using an incremental borrowing rate. Leases with a term of 12 months or less at the commencement date are not recognized on the balance sheet and are expensed as incurred.

The Company has lease agreements with lease and non-lease components, which are accounted for as a single lease component for all asset classes. Leases are accounted for at a portfolio level when similar in nature with identical or nearly identical provisions and similar effective dates and lease terms.

Revenue from Contract with Customer [Policy Text Block]

Revenue Recognition

The Company recognizes revenue when it satisfies a performance obligation by transferring control of the promised goods or services to its customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Sales taxes are imposed on the Company’s sales to nonexempt customers. The Company collects the taxes from the customers and remits the entire amounts to the governmental authorities. Sales taxes are excluded from revenue and expenses.

Revenue from Product Sales

The Company has medical device revenue consisting primarily of sales of the STREAMWAY System, as well as sales of the proprietary cleaning fluid and filters for use with the STREAMWAY System. This revenue stream is reported within both the domestic and international revenue segments. The Company sells its medical device products directly to hospitals and other medical facilities using employed sales representatives and independent contractors. Purchase orders, which are governed by sales agreements in all cases, state the final terms for unit price, quantity, shipping and payment terms. The unit price is considered the observable stand-alone selling price for the arrangements. The Company sales agreement, and Terms and Conditions, is a dually executed contract providing explicit criteria supporting the sale of the STREAMWAY System. The Company considers the combination of a purchase order and acceptance of its Terms and Conditions to be a customer’s contract in all cases.

Product sales for medical devices consist of a single performance obligation that the Company satisfies at a point in time. The Company recognizes product revenue when the following events have occurred: (1) the Company has transferred physical possession of the products, (2) the Company has a present right to payment, (3) the customer has legal title to the products, and (4) the customer bears significant risks and rewards of ownership of the products. Based on the shipping terms specified in the sales agreements and purchase orders, these criteria are generally met when the products are shipped from the Company’s facilities (“FOB origin,” which is the Company’s standard shipping terms). As a result, the Company determined that the customer is able to direct the use of, and obtain substantially all of the benefits from, the products at the time the products are shipped. The Company may, at its discretion, negotiate different shipping terms with customers which may affect the timing of revenue recognition. The Company’s standard payment terms for its customers are generally 30 to 60 days after the Company transfers control of the product to its customer. The Company allows returns of defective disposable merchandise if the customer requests a return merchandise authorization from the Company.

Customers may also purchase a maintenance plan for the medical devices from the Company, which requires the Company to service the STREAMWAY System for a period of one year subsequent to the one-year anniversary date of the original STREAMWAY System invoice. The maintenance plan is considered a separate performance obligation from the product sale, is charged separately from the product sale, and is recognized over time (ratably over the one-year period) as maintenance services are provided. A time-elapsed output method is used to measure progress because the Company transfers control evenly by providing a stand-ready service. The Company has determined that this method provides a faithful depiction of the transfer of services to its customers.

All amounts billed to a customer in a sales transaction for medical devices related to shipping and handling, if any, represent revenues earned for the goods provided, and these amounts have been included in revenue. Costs related to such shipping and handling billing are classified as cost of goods sold. This revenue stream is reported under the Skyline reportable segment.

Revenue from Clinical Testing

Clinic diagnostic testing is comprised of our Tumor Drug Response Testing (ChemoFx) and Genomic Profiling (BioSpeciFx) tests. The Tumor Drug Response Testing test determines how a patient’s tumor specimen reacts to a panel of various chemotherapy drugs, while the Genomic Profiling test evaluates the expression and/or status of a particular gene related to a patient’s tumor specimen. Revenues are recognized when control of the promised goods or services is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. The estimated uncollectible amounts are generally considered implicit price concessions that are a reduction in revenue. Helomics’ payments terms vary by the agreements reached with insurance carriers and Medicare. The Company’s performance obligations are satisfied at one point in time when test reports are delivered.

For service revenues, the Company estimates the transaction price which is the amount of consideration it expects to be entitled to receive in exchange for providing services based on its historical collection experience using a portfolio approach as a practical expedient to account for patient contracts as collective groups rather than individually. The Company monitors its estimates of transaction price to depict conditions that exist at each reporting date. If the Company subsequently determines that it will collect more consideration than it originally estimated for a contract with a patient, it will account for the change as an increase to the estimate of the transaction price, provided that such downward adjustment does not result in a significant reversal of cumulative revenue recognized.

The Company recognizes revenue from these patients when contracts as defined in ASC 606, Revenue from Contracts with Customers are established at the amount of consideration to which it expects to be entitled or when the Company receives substantially all of the consideration subsequent to the performance obligations being satisfied. The Company’s standard payment term for hospital and patient direct bill is 30 days after invoice date. This revenue stream is reported under the Helomics segment.

CRO Revenue

Contract revenues are generally derived from studies conducted with biopharmaceutical and pharmaceutical companies. The specific methodology for revenue recognition is determined on a case-by-case basis according to the facts and circumstances applicable to a given contract. The Company typically uses an input method that recognizes revenue based on the Company’s efforts to satisfy the performance obligation relative to the total expected inputs to the satisfaction of that performance obligation. For contracts with multiple performance obligations, the Company allocates the contract’s transaction price to each performance obligation on the basis of the standalone-selling price of each distinct good or service in the contract. Advance payments received in excess of revenues recognized are classified as deferred revenue until such time as the revenue recognition criteria have been met. Payment terms are net 30 from the invoice date, which is sent to the customer as the Company satisfies the performance obligation relative to the total expected inputs to the satisfaction of that performance obligation. This revenue stream is reported under the Helomics and zPREDICTA segments.

Variable Consideration

The Company records revenue from distributors and direct end customers in an amount that reflects the transaction price it expects to be entitled to after transferring control of those goods or services. The Company’s current contracts do not contain any features that create variability in the amount or timing of revenue to be earned.

Warranty

The Company generally provides one-year warranties against defects in materials and workmanship on product sales and will either repair the products or provide replacements at no charge to customers. As they are considered assurance-type warranties, the Company does not account for them as separate performance obligations. Warranty reserve requirements are based on a specific assessment of the products sold with warranties where a customer asserts a claim for warranty or a product defect.

Contract Balances

The Company records a receivable when it has an unconditional right to receive consideration after the performance obligations are satisfied. As of December 31, 2021 and 2020, accounts receivable totaled $354,196 and $256,878, respectively.

The Company’s deferred revenues related primarily to our zPREDICTA contract research revenue and maintenance plans of our Skyline Medical operating segment. As of December 31, 2021 and 2020, deferred revenue was $186,951 and $53,028, respectively.

Practical Expedients

The Company has elected the practical expedient not to determine whether contracts with customers contain significant financing components as well as the practical expedient to recognize shipping and handling costs at point of sale.

Valuation and Accounting for Stock Options and Warrants, Policy [Policy Text Block]

Valuation and accounting for stock options and warrants

The fair value of each option and warrant grant is estimated on the grant date using the Black-Scholes option valuation model with the following assumptions:

	For the Year Ended December 31,
	2021			2020
	Stock Options
Expected dividend yield		0.0%			0.0%
Expected stock price volatility	84.8%	-	89.6%	82.6%	-	87%
Risk-free interest rate	0.93%	-	1.66%	0.13%	-	1.78%
Expected life (years)		10			10
	*Warrants*
Expected dividend yield		0.0%			0.0%
Expected stock price volatility		84.8%		82.6%	-	87%
Risk-free interest rate	0.42%	-	0.69%	0.135%	-	0.79%
Expected life (years)	5/		5.5	5/		5.5

Research and Development Expense, Policy [Policy Text Block]

Research and Development

Research and development costs are charged to operations as incurred. Research and development costs were $315,850 and $372,710 for the years ended 2021 and 2020, respectively.

Other Expense Policy [Policy Text Block]

Other Expense

Other expense consisted primarily of interest expense, payment penalties, amortization of original issue discounts, and loss on debt extinguishment associated to the Company’s notes payable.

Offering Costs [Policy Text Block]

Offering Costs

Costs incurred which are direct and incremental to an offering of the Company’s securities are deferred and charged against the proceeds of the offering, unless such costs are deemed to be insignificant in which case they are expensed as incurred.

Income Tax, Policy [Policy Text Block]

Income Taxes

The Company accounts for income taxes in accordance with ASC 740, Income Taxes (“ASC 740”). Under ASC 740, deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and net operating loss and credit carryforwards using enacted tax rates in effect for the year in which the differences are expected to impact taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.

Under Internal Revenue Code Section 382, certain stock transactions which significantly change ownership could limit the amount of net operating carryforwards that may be utilized on an annual basis to offset taxable income in future periods. The Company has not yet performed an analysis of the annual net operating loss carryforwards and limitations that are available to be used against taxable income. Consequently, the limitation, if any, could result in the expiration of the Company’s loss carryforwards before they can be utilized. The Company has not analyzed net operating loss carryforwards under Section 382 to date. As a result of the Helomics acquisition, there may be significant limitation to the net operating loss. In addition, the current NOL carryforwards might be further limited by future issuances of our common stock.

Tax years subsequent to 2001 remain open to examination by federal and state tax authorities due to unexpired net operating loss carryforwards.

Concentration Risk, Credit Risk, Policy [Policy Text Block]

Credit Risk

Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any one financial institution. As of December 31, 2021. the Company did not have credit risk for cash amounts held in a single institution that are in excess of amounts issued by the Federal Deposit Insurance Corporation.

Risks and Uncertainties Policy [Policy Text Block]

Risks and Uncertainties

The Company is subject to risks common to companies in the medical device and biopharmaceutical industries, including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, and compliance with regulations of the Food and Drug Administration, Clinical Laboratory Improvement Amendments, and other governmental agencies.

The Company has evaluated all of its activities and concluded that no other subsequent events have occurred that would require recognition in the consolidated financial statements or disclosure in the notes to the consolidated financial statements, except as described above and in Note 16 – Subsequent Events.

Note 13 - Segments

12 Months Ended

Dec. 31, 2021

Segment Reporting Disclosure [Text Block]

NOTE 13 – SEGMENTS

The Company has determined its reportable segments in accordance with ASC 280, Segment Reporting. Factors used to determine the Company’s reportable segments include the availability of separate financial statements, the existence of locally based leadership across geographic regions, the economic factors affecting each segment, and the evaluation of operating results at the segment level. The Chief Operating Decision Maker (“CODM”) allocates the Company’s resources for each of the reportable segments and evaluates their relative performance. Each reportable segment listed below has separate financial statements and locally based leadership that are evaluated based on the results of their respective segments. It should be noted that the reportable segments below have different products and services. The financial information is consolidated and evaluated regularly by the CODM in assessing performance and allocating resources.

During the third quarter of 2020, the Company considered, whether under ASC 280-10-50-3, there was a change in its reportable segments. As a result of the formation of the new Soluble subsidiary, the Company believes the Soluble business represents a reportable segment. Soluble signed its first contract during the third quarter of 2020. The Company also believes it is appropriate to combine our Skyline Medical and Skyline Europe entities into a single reportable segment based on the changes to our physical presence and intent to sign future contracts through the US entity. Finally, the Company believes the Helomics business continues to be a reportable segment.

The Company has four reportable segments: Helomics, zPREDICTA, Soluble and Skyline. See discussion of revenue recognition in Note 1 – Summary of Significant Accounting Policies for a description of the products and services recognized in each segment. The reported financial information below has been reclassified to conform to the current presentation. This information is intended to assist investors in making comparisons of the Company’s historical financial information with future financial information.

The table below summarizes the Company’s segment reporting as of and for years ended December 31, 2021 and 2020.

	Year Ended December 31, 2021
	Skyline			Helomics			Soluble			zPREDICTA			Corporate			Total
Revenue	$	1,169,811		$	13,367		$	233,293		$	90		$	4,119		$	1,420,680
Depreciation and Amortization		(30,002	)		(886,642	)		(366,713	)		(40,625	)		(16,319	)		(1,340,301	)
Impairment expense – goodwill		-			(2,813,792	)		-			-			-			(2,813,792	)
Impairment expense – intangibles		-			(2,893,548	)		-			-			-			(2,893,548	)
Impairment expense – acquired software		-			(1,249,727	)		-			-			-			(1,249,727	)
Net loss	$	(520,822	)	$	(11,326,948	)	$	(1,251,564	)	$	531,446		$	(7,089,286	)	$	(19,657,174	)

	December 31, 2021
	Skyline		Helomics		Soluble		zPREDICTA		Corporate		Total
Assets	$	906,977	$	1,802,792	$	1,742,445	$	10,782,568	$	28,536,489	$	43,771,271

	Year Ended December 31, 2020
	Skyline			Helomics			Soluble			Corporate			Total
Revenue	$	1,185,214		$	64,188		$	2,870		$	-		$	1,252,272
Depreciation and Amortization		(38,310	)		(761,105	)		(184,071	)		(41,362	)		(1,024,848	)
Impairment expense		-			(12,876,498	)		-			-			(12,876,498	)
Net loss	$	(1,132,251	)	$	(15,112,131	)	$	(671,367	)	$	(8,968,648	)	$	(25,884,397	)

	December 31, 2020
	Skyline		Helomics		Soluble		Corporate		Total
Assets	$	1,191,439	$	9,773,902	$	1,883,585	$	211,510	$	13,060,436

In 2021, substantially all the Company revenues were located or derived from operations in the United States. As of December 31, 2021, all of the Company’s long-lived assets were located within the United States.

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI http://asc.fasb.org/topic&trid=2134510

Note 8 - Loss Per Share

12 Months Ended

Dec. 31, 2021

Earnings Per Share [Text Block]

NOTE 8 - LOSS PER SHARE

The following table presents the shares used in the basic and diluted loss per common share computations:

	Year Ended December 31,
	2021			2020
Numerator:
Net loss attributable to common shareholders per common share: basic and diluted calculation	$	(19,657,174	)	$	(26,438,684	)

Denominator:
Weighted average common shares outstanding-basic		54,876,044			11,950,154
Effect of diluted stock options, warrants and preferred stock (1)		-			-
Weighted average common shares outstanding-diluted		54,876,044			11,950,154
Loss per common share-basic and diluted	$	(0.36	)	$	(2.21	)

(1) The following is a summary of the number of underlying shares outstanding at the end of the respective periods that have been excluded from the diluted calculations because the effect on loss per common share would have been anti-dilutive:

	Year Ended December 31,
	2021		2020
Options		1,062,871		1,013,547
Warrants		31,699,885		7,353,376
Convertible debt		-		1,107,544
Preferred stock: Series B		79,246		79,246

Note 7 - Derivatives

12 Months Ended

Dec. 31, 2021

Derivative Instruments and Hedging Activities Disclosure [Text Block]

NOTE 7 - DERIVATIVES

The Company concluded the September 2018 Investor Note contained a conversion feature which is an embedded derivative and required bifurcation. The embedded derivative’s value was determined using the discounted stock price for the 20-trading days preceding the balance sheet date and the assumption of conversion on that date, as management believed it was probable that the notes would be convertible based on management’s expectation that additional financing would be required. During the year ended December 31, 2020, the maximum number of conversions was reached. The Company recognized an unrealized gain for the corresponding change in fair value of $50,989 for the year ended December 31, 2020. The fair value of the derivative liability related to the bridge loan was zero as of December 31, 2020.

The Company concluded the Promissory Note 2020 contained a conversion feature and a put each of which was an embedded derivative and are required to be bifurcated. In accordance with ASC 815, Derivatives and Hedging, the Company combined these two embedded derivatives into a single derivative and determined the fair value to record within the derivative liability on the consolidated balance sheet. At inception, the fair value of the derivative liability was $68,796, $52,125 and $20,542 for the first, second and third tranches, respectively. During the year ended December 31, 2020, the Company recognized a gain of $87,923 on the change in the fair value of the derivative liability. As a result of the repayment of the note as of March 1, 2021, the embedded derivative had a fair value of zero prior to the repayment. The Company recorded a gain on the fair value of the derivative of $104,529 during the year ended December 31, 2021. As of December 31, 2020, the fair value of the derivative liability was $104,529.

The Company concluded the A, B and agent warrants issued in connection with the March 2020 Private Placement discussed above are a derivative liability due to certain features of the warrants which could, in certain circumstances, result in the holder receiving the Black Scholes value of the outstanding warrants in the same type of consideration as the common stockholders. As a result, in those circumstances, the amount of consideration would differ from that provided to holders of common stock, therefore, the warrants were classified as a liability. At inception, the A, B and agent warrants had a fair value of $2,669,995. During the third quarter of 2020, the A and B warrants were amended as discussed in Note 6 - Notes Payable above. As a result of this amendment, the warrants no longer represented a liability to the Company and were reclassified to equity. Prior to reclassification, a gain on the change in fair value of $700,910 was recorded during the year ended December 31, 2020. As of December 31, 2021, the fair value of the agent warrants was determined to be $41,336 and the Company recorded a loss on the change in fair value of $7,683 during the year ended December 31, 2021. As of December 31, 2020, the fair value of the agent warrants was determined to be $33,654 and the Company recorded a gain on the change in fair value of $69,479 during the year ended December 31, 2020.

The Company concluded the warrants and agent warrants issued in connection with the May 2020 Offering discussed above are a derivative liability due to certain features of the warrants which could, in certain circumstances, result in the holder receiving the Black Scholes value of the outstanding warrants in the same type of consideration as the common stockholders. As a result, in those circumstances, the amount of consideration would differ from that provided to holders of common stock, therefore, the warrants were classified as a liability. At inception, the warrants and agent warrants had a fair value of $1,324,184. The Company recorded a loss on the change in fair value of the warrants of $460,065 during the year ended December 31, 2020. During June 2020, the investors exercised the warrants and exchanged the warrants for shares of common stock as discussed above. The fair value of the agent warrants was determined to be $33,819 and $42,646 as of December 31, 2021 and as of December 31, 2020, respectively. The Company recorded a loss on the change in fair value of the agent warrants of $8,827 during the year ended December 31, 2021 and a gain on the change in fair value of the agent warrants of $48,675 during the year ended December 31, 2020.

In connection with the June 2020 Warrant exercise and issuance, the Company concluded the warrants and agent warrants issued in connection with the June 2020 Warrant exercise and issuance, discussed above, are a derivative liability due to certain features of the warrants which could, in certain circumstances, result in the holder receiving the Black Scholes value of the outstanding warrants in the same type of consideration as the common stockholders. As a result, in those circumstances, the amount of consideration would differ from that provided to holders of common stock, therefore, the warrants were classified as a liability. At inception, the warrants and agent warrants had a fair value of $1,749,721. During the year ended December 31, 2020, the June warrants were amended. As a result of this amendment, the warrants no longer represented a liability to the Company and were reclassified to equity. Prior to reclassification, the Company recorded a gain on the change in fair value of the warrants of $834,520 during the year ended December 31, 2020. The Company recorded a loss on the change in fair value of the agent warrants of $12,797 during the year ended December 31, 2021 and a gain on the change in fair value of the agent warrants of $79,045 during the year ended December 31, 2020. The fair value of the agent warrants was $45,498 and $32,701 as of December 31, 2021 and as of December 31, 2020, respectively.

On September 30, 2020, the Promissory Note 2019 was amended. The Company concluded the Promissory Note 2019 contained a conversion feature which is an embedded derivative and is required to be bifurcated. In accordance with ASC 815, Derivatives and Hedging, the Company determined the fair value to record within the derivative liability on the consolidated balance sheet. At inception, the fair value of the derivative liability was $495,100. As a result of the repayment of the note as of March 1, 2021, the embedded derivative had a fair value of zero prior to the repayment. The Company recorded a gain on the fair value of the derivative of $89,680 during the year ended December 31, 2021. The Company recorded a gain on the change in fair value of the derivative liability of $405,420 during the year ended December 31, 2020. As of December 31, 2020, the fair value of the derivative liability was $89,680.

The table below discloses changes in value of the Company’s embedded derivative liabilities discussed above.

Derivative liability balance at December 31, 2019	$	50,989
Derivative instrument recognized for A, B and Agent Warrants		2,669,995
Derivative instrument related to Promissory Note 2020		120,921
Derivative instrument recognized for May 2020 Warrants		1,324,184
Derivative instrument recognized for June 2020 Warrants		1,749,721
Derivative instrument related to Promissory Note 2020		20,542
Reclassification of Warrant liabilities to Equity on exercise		(1,701,756	)
Reclassification of Warrant liabilities to Equity		(2,669,408	)
Derivative instrument related to September 30 debt amendments		495,100
Gain recognized to revalue derivative instrument at fair value		(1,765,906	)
Derivative liability balance at December 31, 2020	$	294,382
Gain recognized to revalue derivative instrument at fair value		(164,902	)
Derivative liability balance at December 31, 2021	$	129,480

Note 1 - Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2021

Significant Accounting Policies [Text Block]

NOTE 1 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Nature of Operations and Continuance of Operations

Predictive Oncology Inc., (the “Company” or “Predictive” or “we”) filed with the Secretary of State of Delaware a Certificate of Amendment to its Certificate of Incorporation to change the corporate name to Predictive Oncology Inc. on June 10, 2019, trading under the new ticker symbol “POAI,” effective June 13, 2019.

The Company operates in four primary business areas: first, application of artificial intelligence (“AI”) in our precision medicine business, to provide AI-driven predictive models of tumor drug response to improve clinical outcomes for patients and to assist pharmaceutical, diagnostic, and biotech industries in the development of new personalized drugs and diagnostics primarily through its wholly owned subsidiary Helomics Holding Corporation (“Helomics”); second, tumor-specific in vitro models for oncology drug discovery and research through its newly acquired wholly-owned subsidiary, zPREDICTA; third, contract services and research focused on solubility improvements, stability studies, and protein production, primarily with our Soluble Biotech subsidiary, and; fourth, production of the United States Food and Drug Administration (“FDA”)-cleared STREAMWAY System for automated, direct-to-drain medical fluid waste disposal and associated products through its incorporated division Skyline.

The Company had cash and cash equivalents of $28,202,615 as of December 31, 2021. As of December 31, 2021, there was no outstanding debt. The Company believes that its existing capital resources will be sufficient to support its operating plan for the next twelve months and beyond. However, the Company may also seek to raise additional capital to support its growth through additional debt, equity or other alternatives or a combination thereof. The Company currently expects to use cash on hand to fund capital and equipment investments, research and development, potential acquisitions and its operations, and expects such sources to be sufficient to fund its requirements over that time.

Coronavirus Outbreak

The current COVID-19 worldwide pandemic has presented substantial public health challenges. In response to the crisis, emergency measures have been imposed by governments worldwide, including mandatory social distancing and the shutdown of non-essential businesses. These measures have adversely impacted the global economy, disrupted global supply chains and created significant volatility and disruption of financial markets, and our business and operations have been and will likely continue to be materially and adversely affected. For example, our contract manufacturer for the STREAMWAY® System has been forced to change locations, thereby delaying our order fulfillment for parts. We have also reduced on-site staff at several of our facilities, resulting in delayed production, less efficiency, and our sales staff is unable to visit with hospital administrators who are our customers and potential customers. In addition, COVID-19 has impacted the Company’s capital and financial resources, including our overall liquidity position and outlook. For instance, our accounts receivable has slowed while our suppliers continue to ask for pre-delivery deposits. Ultimately, the extent of the impact of the COVID-19 pandemic on our future operational and financial performance will depend on, among other matters, the duration and intensity of the pandemic; the level of success of global vaccination efforts; governmental and private sector responses to the pandemic and the impact of such responses on us; and the impact of the pandemic on our employees, customers, suppliers, operations and sales, all of which are uncertain and cannot be predicted. These factors may remain prevalent for a significant period of time even after the pandemic subsides, including due to a continued or prolonged recession in the U.S. or other major economies. Even in areas where "stay-at-home" restrictions, masking and social distancing measures have been lifted and the number of COVID-19 cases have declined, some jurisdictions may re-impose these measures as and if variant strains emerge or cases rise. The impacts of the COVID-19 pandemic, as with any adverse public health developments, could have a material adverse effect on our business, results of operations, liquidity or financial condition and heighten or exacerbate risks described in this Annual Report on Form 10-K.

Recently Adopted Accounting Standards

The Company considers the applicability and impact of all Accounting Standards Updates (“ASUs”) issued by the Financial Accounting Standards Board (the “FASB”). Recently issued ASUs not listed below either were assessed and determined to be not applicable or are currently expected to have no impact on the condensed consolidated financial statements of the Company.

In June 2016, the FASB issued ASU 2016-13, “Financial Instruments – Credit Losses.” This ASU added a new impairment model (known as the current expected credit loss (“CECL”) model) that is based on expected losses rather than incurred losses. Under the new guidance, an entity recognizes as an allowance its estimate of expected credit losses. The CECL model applies to most debt instruments, trade receivables, lease receivables, financial guarantee contracts, and other loan commitments. The CECL model does not have a minimum threshold for recognition of impairment losses and entities will need to measure expected credit losses on assets that have a low risk of loss. As a smaller reporting company pursuant to Rule 12b-2 of the Securities Exchange Act of 1934, as amended, these changes become effective for the Company on January 1, 2023. Management is currently evaluating the potential impact of these changes on the consolidated financial statements of the Company.

Accounting Policies and Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and disclosure of contingent assets and liabilities at the date of the financial statements and during the reporting period. Actual results could materially differ from those estimates.

Reclassifications

Certain reclassifications have been made to the prior years’ financial statements to conform to the current year presentation. The reclassifications had no effect on previously reported results of operations, cash flows or stockholders’ equity.

Cash and cash equivalents

The Company considers all highly liquid instruments with maturities when purchased of three months or less to be cash equivalents. The Company places its cash with high quality financial institutions and believes its risk of loss is limited to amounts in excess of that which is insured by the Federal Deposit Insurance Corporation.

Receivables

Receivables are reported at the amount the Company expects to collect on balances outstanding. The Company provides for probable uncollectible amounts through charges to earnings and credits to the valuation allowance based on management’s assessment of the current status of individual accounts.

Amounts recorded in accounts receivable on the consolidated balance sheet include amounts billed and currently due from customers. The amounts due are stated at their net estimated realizable value. An allowance for doubtful accounts is maintained to provide for the estimated amount of receivables that will not be collected. The Company reviews customers’ credit history before extending unsecured credit and establishes an allowance for uncollectible accounts based upon factors surrounding the credit risk of specific customers, historical trends and other information. Invoices are generally due 30 days after presentation. Accounts receivable over 30 days is generally considered past due. The Company does not accrue interest on past due accounts receivables. Receivables are written off once all collection attempts have failed and are based on individual credit evaluation and specific circumstances of the customer. The allowance for doubtful accounts balance was $0 as of both December 31, 2021 and 2020.

Fair Value Measurements

As outlined in Accounting Standards Codification (“ASC”) 820, Fair Value Measurement, fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting standards ASC 820 establishes a three-level fair value hierarchy that prioritizes information used in developing assumptions when pricing an asset or liability as follows:

Level 1 – Observable inputs such as quoted prices in active markets;

Level 2 – Inputs other than quoted prices in active markets, that are observable either directly or indirectly; and

Level 3 – Unobservable inputs where there is little or no market data, which requires the reporting entity to develop its own assumptions.

The Company uses observable market data, when available, in making fair value measurements. Fair value measurements are classified according to the lowest level input that is significant to the valuation.

The fair value of the Company’s investment securities, which consist of cash and cash equivalents, was determined based on Level 1 inputs. The fair value of the Company’s derivative liabilities and debt were determined based on Level 3 inputs. The Company generally uses Black Scholes method for determining the fair value of warrants classified as liabilities on a recurring basis. In addition, the Company uses the Monte Carlo method and other acceptable valuation methodologies when valuing the conversion feature and other embedded features classified as derivatives on a recurring basis. See Note 7 – Derivatives. When performing quantitative testing related to goodwill impairment analysis, the Company estimates the fair values of its reporting units using discounted cash flows. To determine fair values, the Company is required to make assumptions about a wide variety of internal and external factors. Significant assumptions used in the impairment analysis include financial projections of free cash flow (including significant assumptions about operations including the rate of future revenue growth, capital requirements, and income taxes), long-term growth rates for determining terminal value and discount rates. The majority of the inputs used in the discounted cash flow model are unobservable and thus are considered to be Level 3 inputs. See Note 10 – Goodwill and Intangibles.

The acquisition of zPREDICTA was accounted for as a business combination using the acquisition method of accounting. This method requires, among other things, that assets acquired and liabilities assumed be recognized at fair value as of the acquisition date. The fair value for the assets acquired and the liabilities assumed are based on information knowable and determined by management as of the acquisition date. The majority of the inputs used in the discounted cash flow model, the relief-from-royalty method under the income approach, the distributor method under the income approach and the multi-period excess earnings method under the income approach, each are unobservable and thus are considered to be Level 3 inputs. See Note 2 – zPREDICTA Acquisition.

Inventories

Inventories are stated at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis.

Fixed Assets

Fixed assets are stated at cost less accumulated depreciation. Depreciation of fixed assets is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows:

Years

Computers, software and office equipment

3

-

10

Leasehold improvements (1)

2

-

5

Manufacturing tooling

3

-

7

Laboratory equipment

4

-

10

Demo equipment

3

(1)

Leasehold improvements are amortized over the shorter of the useful life or the remaining lease term.

Upon retirement or sale of fixed assets, the cost and related accumulated depreciation or amortization are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations expense as incurred.

Long-lived Assets

Finite-lived intangible assets consist of patents and trademarks, licensing fees, developed technology, acquired software and customer relationships, and are amortized over their estimated useful life. Accumulated amortization is included in intangibles, net in the accompanying consolidated balance sheets.

The Company reviews finite-lived identifiable intangible assets for impairment in accordance with ASC 360, Property, Plant and Equipment, whenever events or changes in circumstances indicate the carrying amount may not be recoverable. Events or changes in circumstances that indicate the carrying amount may not be recoverable include, but are not limited to, a significant change in the medical device marketplace and a significant adverse change in the business climate in which the Company operates.

The Company prepared an undiscounted cash flow as of December 31, 2021 to evaluate long-lived assets based on a triggering event per ASC 360. The Company concluded that the undiscounted cash flows did not support the carrying values of its Helomics asset group at December 31, 2021. The Company determined the value of the intangibles and the software license acquired were fully impaired as of December 31, 2021 and recognized and impairment loss of $2,893,548 for its long-lived intangible assets and $1,249,727 for the acquired software. The Company concluded there was no impairment of its other finite lived tangible assets as of December 31, 2021. See Note 10 – Intangible Assets and Goodwill.

The Company also prepared an undiscounted cash flow as of December 31, 2020 to evaluate long-lived assets based on a triggering event at that time. The Company concluded that the undiscounted cash flows of the long-lived assets exceeded the carrying values. The Company concluded there was no impairment of its finite lived assets as of December 31, 2020.

Goodwill

In accordance with ASC 350, Intangibles – Goodwill and Other, goodwill is calculated as the difference between the acquisition date fair value of the consideration transferred and the fair value of net assets acquired. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination. Goodwill is not amortized but is tested on an annual basis for impairment at the reporting unit level as of December 31, or whenever events or changes in circumstances indicate that the carrying amount may not be fully recoverable.

To determine whether goodwill is impaired, annually or more frequently if needed, the Company performs a multi-step impairment test. The Company first has the option to assess qualitative factors to determine if it is more likely than not that the carrying value of a reporting unit exceeds its estimated fair value. The Company may also elect to skip the qualitative testing and proceed directly to the quantitative testing. When performing quantitative testing, the Company first estimates the fair values of its reporting units using discounted cash flows. To determine fair values, the Company is required to make assumptions about a wide variety of internal and external factors. Significant assumptions used in the impairment analysis include financial projections of free cash flow (including significant assumptions about operations including the rate of future revenue growth, capital requirements, and income taxes), long-term growth rates for determining terminal value and discount rates. Comparative market multiples are used to corroborate the results of the discounted cash flow test. These assumptions require significant judgement. Pursuant to ASU 2017-04, Simplifying the Test for Goodwill Impairment, the single step is to determine the estimated fair value of the reporting unit and compare it to the carrying value of the reporting unit, including goodwill. To the extent the carrying amount of goodwill exceeds the implied goodwill, the difference is the amount of the goodwill impairment. The Company also completes a reconciliation between the implied equity valuation prepared and the Company’s market capitalization. The majority of the inputs used in the discounted cash flow model are unobservable and thus are considered to be Level 3 inputs. The inputs for the market capitalization calculation are considered Level 1 inputs. See Note 3 – Intangible Assets and Goodwill.

Leases – At inception of a contract a determination is made whether an arrangement meets the definition of a lease. A contract contains a lease if there is an identified asset and the Company has the right to control the asset. Operating leases are recorded as right-of-use (“ROU”) assets with corresponding current and noncurrent operating lease liabilities on our consolidated balance sheets. Financing leases are included within fixed assets with corresponding current liability within other current liabilities and noncurrent liability within other long-term liabilities on our consolidated balance sheets.

ROU assets represent our right to use an underlying asset for the duration of the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Recognition on the commencement date is based on the present value of lease payments over the lease term using an incremental borrowing rate. Leases with a term of 12 months or less at the commencement date are not recognized on the balance sheet and are expensed as incurred.

The Company has lease agreements with lease and non-lease components, which are accounted for as a single lease component for all asset classes. Leases are accounted for at a portfolio level when similar in nature with identical or nearly identical provisions and similar effective dates and lease terms.

Revenue Recognition

The Company recognizes revenue when it satisfies a performance obligation by transferring control of the promised goods or services to its customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Sales taxes are imposed on the Company’s sales to nonexempt customers. The Company collects the taxes from the customers and remits the entire amounts to the governmental authorities. Sales taxes are excluded from revenue and expenses.

Revenue from Product Sales

The Company has medical device revenue consisting primarily of sales of the STREAMWAY System, as well as sales of the proprietary cleaning fluid and filters for use with the STREAMWAY System. This revenue stream is reported within both the domestic and international revenue segments. The Company sells its medical device products directly to hospitals and other medical facilities using employed sales representatives and independent contractors. Purchase orders, which are governed by sales agreements in all cases, state the final terms for unit price, quantity, shipping and payment terms. The unit price is considered the observable stand-alone selling price for the arrangements. The Company sales agreement, and Terms and Conditions, is a dually executed contract providing explicit criteria supporting the sale of the STREAMWAY System. The Company considers the combination of a purchase order and acceptance of its Terms and Conditions to be a customer’s contract in all cases.

Product sales for medical devices consist of a single performance obligation that the Company satisfies at a point in time. The Company recognizes product revenue when the following events have occurred: (1) the Company has transferred physical possession of the products, (2) the Company has a present right to payment, (3) the customer has legal title to the products, and (4) the customer bears significant risks and rewards of ownership of the products. Based on the shipping terms specified in the sales agreements and purchase orders, these criteria are generally met when the products are shipped from the Company’s facilities (“FOB origin,” which is the Company’s standard shipping terms). As a result, the Company determined that the customer is able to direct the use of, and obtain substantially all of the benefits from, the products at the time the products are shipped. The Company may, at its discretion, negotiate different shipping terms with customers which may affect the timing of revenue recognition. The Company’s standard payment terms for its customers are generally 30 to 60 days after the Company transfers control of the product to its customer. The Company allows returns of defective disposable merchandise if the customer requests a return merchandise authorization from the Company.

Customers may also purchase a maintenance plan for the medical devices from the Company, which requires the Company to service the STREAMWAY System for a period of one year subsequent to the one-year anniversary date of the original STREAMWAY System invoice. The maintenance plan is considered a separate performance obligation from the product sale, is charged separately from the product sale, and is recognized over time (ratably over the one-year period) as maintenance services are provided. A time-elapsed output method is used to measure progress because the Company transfers control evenly by providing a stand-ready service. The Company has determined that this method provides a faithful depiction of the transfer of services to its customers.

All amounts billed to a customer in a sales transaction for medical devices related to shipping and handling, if any, represent revenues earned for the goods provided, and these amounts have been included in revenue. Costs related to such shipping and handling billing are classified as cost of goods sold. This revenue stream is reported under the Skyline reportable segment.

Revenue from Clinical Testing

Clinic diagnostic testing is comprised of our Tumor Drug Response Testing (ChemoFx) and Genomic Profiling (BioSpeciFx) tests. The Tumor Drug Response Testing test determines how a patient’s tumor specimen reacts to a panel of various chemotherapy drugs, while the Genomic Profiling test evaluates the expression and/or status of a particular gene related to a patient’s tumor specimen. Revenues are recognized when control of the promised goods or services is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. The estimated uncollectible amounts are generally considered implicit price concessions that are a reduction in revenue. Helomics’ payments terms vary by the agreements reached with insurance carriers and Medicare. The Company’s performance obligations are satisfied at one point in time when test reports are delivered.

For service revenues, the Company estimates the transaction price which is the amount of consideration it expects to be entitled to receive in exchange for providing services based on its historical collection experience using a portfolio approach as a practical expedient to account for patient contracts as collective groups rather than individually. The Company monitors its estimates of transaction price to depict conditions that exist at each reporting date. If the Company subsequently determines that it will collect more consideration than it originally estimated for a contract with a patient, it will account for the change as an increase to the estimate of the transaction price, provided that such downward adjustment does not result in a significant reversal of cumulative revenue recognized.

The Company recognizes revenue from these patients when contracts as defined in ASC 606, Revenue from Contracts with Customers are established at the amount of consideration to which it expects to be entitled or when the Company receives substantially all of the consideration subsequent to the performance obligations being satisfied. The Company’s standard payment term for hospital and patient direct bill is 30 days after invoice date. This revenue stream is reported under the Helomics segment.

CRO Revenue

Contract revenues are generally derived from studies conducted with biopharmaceutical and pharmaceutical companies. The specific methodology for revenue recognition is determined on a case-by-case basis according to the facts and circumstances applicable to a given contract. The Company typically uses an input method that recognizes revenue based on the Company’s efforts to satisfy the performance obligation relative to the total expected inputs to the satisfaction of that performance obligation. For contracts with multiple performance obligations, the Company allocates the contract’s transaction price to each performance obligation on the basis of the standalone-selling price of each distinct good or service in the contract. Advance payments received in excess of revenues recognized are classified as deferred revenue until such time as the revenue recognition criteria have been met. Payment terms are net 30 from the invoice date, which is sent to the customer as the Company satisfies the performance obligation relative to the total expected inputs to the satisfaction of that performance obligation. This revenue stream is reported under the Helomics and zPREDICTA segments.

Variable Consideration

The Company records revenue from distributors and direct end customers in an amount that reflects the transaction price it expects to be entitled to after transferring control of those goods or services. The Company’s current contracts do not contain any features that create variability in the amount or timing of revenue to be earned.

Warranty

The Company generally provides one-year warranties against defects in materials and workmanship on product sales and will either repair the products or provide replacements at no charge to customers. As they are considered assurance-type warranties, the Company does not account for them as separate performance obligations. Warranty reserve requirements are based on a specific assessment of the products sold with warranties where a customer asserts a claim for warranty or a product defect.

Contract Balances

The Company records a receivable when it has an unconditional right to receive consideration after the performance obligations are satisfied. As of December 31, 2021 and 2020, accounts receivable totaled $354,196 and $256,878, respectively.

The Company’s deferred revenues related primarily to our zPREDICTA contract research revenue and maintenance plans of our Skyline Medical operating segment. As of December 31, 2021 and 2020, deferred revenue was $186,951 and $53,028, respectively.

Practical Expedients

The Company has elected the practical expedient not to determine whether contracts with customers contain significant financing components as well as the practical expedient to recognize shipping and handling costs at point of sale.

Valuation and accounting for stock options and warrants

The Company determines the grant date fair value of options and warrants using a Black-Scholes option valuation model based upon assumptions regarding risk-free interest rate, expected dividend rate, volatility and estimated term.

The fair value of each option and warrant grant is estimated on the grant date using the Black-Scholes option valuation model with the following assumptions:

For the Year Ended December 31,

2021

2020

Stock Options

Expected dividend yield

0.0%

0.0%

Expected stock price volatility

84.8%
- 89.6%
82.6%
- 87%

Risk-free interest rate

0.93%
- 1.66%
0.13%
- 1.78%

Expected life (years)

10

10

Warrants

Expected dividend yield

0.0%

0.0%

Expected stock price volatility

84.8%
82.6%
- 87%

Risk-free interest rate

0.42%
- 0.69%
0.135%
- 0.79%

Expected life (years)

5/
5.5
5/
5.5

Research and Development

Research and development costs are charged to operations as incurred. Research and development costs were $315,850 and $372,710 for the years ended 2021 and 2020, respectively.

Other Expense

Other expense consisted primarily of interest expense, payment penalties, amortization of original issue discounts, and loss on debt extinguishment associated to the Company’s notes payable.

Offering Costs

Costs incurred which are direct and incremental to an offering of the Company’s securities are deferred and charged against the proceeds of the offering, unless such costs are deemed to be insignificant in which case they are expensed as incurred.

Income Taxes

The Company accounts for income taxes in accordance with ASC 740, Income Taxes (“ASC 740”). Under ASC 740, deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and net operating loss and credit carryforwards using enacted tax rates in effect for the year in which the differences are expected to impact taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.

The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax positions will be sustained on examination by taxing authorities, based on technical merits of the positions. The Company has identified no income tax uncertainties.

Under Internal Revenue Code Section 382, certain stock transactions which significantly change ownership could limit the amount of net operating carryforwards that may be utilized on an annual basis to offset taxable income in future periods. The Company has not yet performed an analysis of the annual net operating loss carryforwards and limitations that are available to be used against taxable income. Consequently, the limitation, if any, could result in the expiration of the Company’s loss carryforwards before they can be utilized. The Company has not analyzed net operating loss carryforwards under Section 382 to date. As a result of the Helomics acquisition, there may be significant limitation to the net operating loss. In addition, the current NOL carryforwards might be further limited by future issuances of our common stock.

Tax years subsequent to 2001 remain open to examination by federal and state tax authorities due to unexpired net operating loss carryforwards.

Credit Risk

Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any one financial institution. As of December 31, 2021. the Company did not have credit risk for cash amounts held in a single institution that are in excess of amounts issued by the Federal Deposit Insurance Corporation.

Risks and Uncertainties

The Company is subject to risks common to companies in the medical device and biopharmaceutical industries, including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, and compliance with regulations of the Food and Drug Administration, Clinical Laboratory Improvement Amendments, and other governmental agencies.

The Company has evaluated all of its activities and concluded that no other subsequent events have occurred that would require recognition in the consolidated financial statements or disclosure in the notes to the consolidated financial statements, except as described above and in Note 16 – Subsequent Events.

Note 16 - Subsequent Events

12 Months Ended

Dec. 31, 2021

Subsequent Events [Text Block]

NOTE 16 – SUBSEQUENT EVENTS

Equity Line Agreement

During the first quarter of 2022 through March 28, the Company issued 120,000 shares of its common stock valued at $86,885 pursuant to the equity line.

Note 7 - Derivatives - Change in Fair Value of Derivative Liabilities (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2021
Derivative liability balance	$ 294,382	$ 50,989
Derivative instrument recognized for May 2020 Warrants		294,382	$ 129,480
Reclassification of Warrant liabilities to Equity on exercise	(1,701,756)
Reclassification of Warrant liabilities to Equity	(2,669,408)
Gain recognized to revalue derivative instrument at fair value	(164,902)	(1,765,906)
Derivative liability balance		$ 294,382
A, B and Agent Warrants [Member]
Derivative instrument recognized	2,669,995
Promissory Note 2020 [Member]
Derivative instrument recognized	120,921
Warrants and Agent Warrants In Connection With May 2020 Warrant [Member]
Derivative instrument recognized for May 2020 Warrants	1,324,184
Derivative liability balance	1,324,184
Warrants and Agent Warrants In Connection With June 2020 Warrant [Member]
Derivative instrument recognized	495,100
Derivative instrument recognized for May 2020 Warrants	1,749,721
Derivative liability balance	1,749,721
Promissory Note 2020 2 [Member]
Derivative instrument recognized	$ 20,542

Note 11 - Leases (Details Textual)	12 Months Ended
Note 11 - Leases (Details Textual)	Dec. 31, 2021 USD ($) ft²	Dec. 31, 2020 USD ($)
Operating Lease, Expense \| $	$ 595,669	$ 565,581
Corporate Office, Minnesota [Member]
Lessee, Operating Lease, Term of Contract (Year)	3 years
Area of Real Estate Property (Square Foot)	5,773
Corporate Office, Minnesota, Used for Office Space [Member]
Area of Real Estate Property (Square Foot)	2,945
Corporate Office, Minnesota, Used for Manufacturing [Member]
Area of Real Estate Property (Square Foot)	2,828
Helomics' Offices [Member]
Lessee, Operating Lease, Term of Contract (Year)	3 years
Area of Real Estate Property (Square Foot)	17,417
Helomics Offices, Lease Area for Office Space [Member]
Area of Real Estate Property (Square Foot)	1,000
Helomics Offices, Lease Area for Laboratory [Member]
Area of Real Estate Property (Square Foot)	16,417
zPREDICTA Offices in San Jose California [Member]
Area of Real Estate Property (Square Foot)	1,236
Soluble Biodtech Offices in Birmingham, Alabama [Member]
Area of Real Estate Property (Square Foot)	4,314
TumorGenesis Offices In Salem Massachusetts [Member]
Area of Real Estate Property (Square Foot)	1,450
Skyline Medical Europe’s Offices Lease [Member]
Area of Real Estate Property (Square Foot)	2,000
Skyline Medical Europe's Offices Lease, Storage Space [Member]
Area of Real Estate Property (Square Foot)	750
Skyline Medical Europe's Offices Lease, Office Space [Member]
Area of Real Estate Property (Square Foot)	1,250

Note 10 - Goodwill and Intangibles - Components of Intangible Assets (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Accumulated Amortization	$ (1,102,649)	$ (728,320)
Net Carrying Amount	3,962,118
Impairment, indefinite	2,893,548	0
Total, Gross Carrying Costs	7,958,314	4,126,421
Impairment	2,893,548	0
Total, Net Carrying Amount	3,962,118	3,398,101
Trade Names 1 [Member]
Tradename		398,000
Tradename		(5,452)
Tradename	77,917	392,548
Patents and Trademarks [Member]
Gross Carrying Costs	453,314	401,421
Accumulated Amortization	(230,572)	(211,110)
Impairment, finite	(0)
Net Carrying Amount	222,742	190,311
Developed Technology Rights [Member]
Gross Carrying Costs	6,382,000	2,882,000
Accumulated Amortization	(432,733)	(252,175)
Impairment, finite	2,485,725
Net Carrying Amount	3,463,542	2,629,825
Customer Relationships [Member]
Gross Carrying Costs	645,000	445,000
Accumulated Amortization	(410,000)	(259,583)
Impairment, finite	37,083
Net Carrying Amount	197,917	$ 185,417
Trade Names [Member]
Tradename	478,000
Tradename	(29,344)
Impairment, indefinite	$ 370,740

Note 12 - Property, Plant and Equipment

12 Months Ended

Dec. 31, 2021

Property, Plant and Equipment Disclosure [Text Block]

NOTE 12 – Property, Plant and Equipment

Fixed Assets

The Company’s fixed assets consist of the following:

	December 31, 2021		December 31, 2020
Computers, software and office equipment	$	517,488	$	1,862,669
Laboratory equipment		3,456,091		2,811,011
Leasehold improvements		428,596		315,297
Manufacturing tooling		121,120		108,956
Demo equipment		56,614		56,614
Total		4,579,909		5,154,547
Less: Accumulated depreciation		2,068,338		1,331,847
Total fixed assets, net	$	2,511,571	$	3,822,700

Upon retirement or sale or fixed assets, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations expense. Maintenance and repairs are expensed as incurred.

Depreciation expense was $965,973 and $711,139 in 2021 and 2020, respectively.

Note 9 - Income Taxes - Reconciliation of Income Tax Benefit (Expense) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Statutory federal income tax benefit	$ 4,266,955	$ 5,434,463
State tax benefit, net of federal taxes	793,282	578,746
Foreign tax benefit	0	62,146
Foreign operations tax rate differential	0	(44,120)
State rate adjustment	5,153	65,112
Nondeductible/nontaxable items	(260,768)	(268,968)
Goodwill impairment	605,420	2,762,014
NOL adjustments	(612,588)	(1,141,662)
Other	150,083	(461,020)
Valuation allowance increase	(3,075,039)	(1,462,683)
Total income tax benefit	$ 661,658	$ 0

Note 10 - Goodwill and Intangibles - Goodwill (Details) - USD ($)	3 Months Ended	9 Months Ended		12 Months Ended
	Dec. 31, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2021	Dec. 31, 2020
Goodwill		$ 2,813,792	$ 15,690,290	$ 2,813,792	$ 15,690,290
Impairment	$ (9,879,498)	$ (2,813,792)	$ (2,997,000)	(2,813,792)	$ (12,876,498)
zPREDICTA [Member]
Goodwill, Acquired During Period				$ 6,857,790

Note 15 - Retirement Savings Plans (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Defined Contribution Plan, Employer Matching Contribution, Percent of Match			100.00%	100.00%
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent			4.00%	4.00%
Defined Contribution Plan, Employer Contribution Amount	$ 127,953	$ 119,555
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 0	$ 0

Note 12 - Property, Plant and Equipment (Tables)

12 Months Ended

Dec. 31, 2021

Property, Plant and Equipment [Table Text Block]

	December 31, 2021		December 31, 2020
Computers, software and office equipment	$	517,488	$	1,862,669
Laboratory equipment		3,456,091		2,811,011
Leasehold improvements		428,596		315,297
Manufacturing tooling		121,120		108,956
Demo equipment		56,614		56,614
Total		4,579,909		5,154,547
Less: Accumulated depreciation		2,068,338		1,331,847
Total fixed assets, net	$	2,511,571	$	3,822,700

Note 6 - Notes Payable (Tables)

12 Months Ended

Dec. 31, 2021

Schedule of Short-term Debt [Table Text Block]

	Due Date	December 31, 2021		December 31, 2020
2018 Investor loan	March 31, 2021	$	-	$	1,721,776
Promissory note 2019	March 27, 2021		-		1,490,833
Promissory note 2020	March 31, 2021		-		1,464,146
Total Notes Payable, gross			-		4,676,755
Less: Unamortized discount			-		244,830
Total Notes Payable, net		$	-	$	4,431,925

Note 2 - zPredicta Acquisition - Pro Form Information (Details) - zPREDICTA [Member] - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Revenue	$ 2,429,786	$ 1,815,560
Net loss attributable to common shareholders	$ (18,878,432)	$ (26,946,564)

Note 9 - Income Taxes (Tables)

12 Months Ended

Dec. 31, 2021

Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]

	Year Ended December 31,
	2021			2020
Statutory federal income tax benefit	$	4,266,955		$	5,434,463
State tax benefit, net of federal taxes		793,282			578,746
Foreign tax benefit		-			62,146
Foreign operations tax rate differential		-			(44,120	)
State rate adjustment		5,153			65,112
Nondeductible/nontaxable items		(260,768	)		(268,968	)
Goodwill impairment		(605,420	)		(2,762,014	)
NOL adjustments		(612,588	)		(1,141,662	)
Other		150,083			(461,020	)
Valuation allowance increase		(3,075,039	)		(1,462,683	)
Total income tax benefit	$	661,658		$	-

Schedule of Deferred Tax Assets and Liabilities [Table Text Block]

	December 31, 2021			December 31, 2020
Deferred tax assets:
Noncurrent:
Inventory	$	-		$	7,196
Compensation accruals		58,829			63,846
Accruals and reserves		50,537			162,628
Deferred revenue		26,198			11,641
Charitable contribution carryover		1,095			4,331
Derivatives		27,859			63,145
Intangibles		700,876			295,941
Right of use asset		18,543			13,861
NSQO compensation		1,602,429			1,738,217
NOL and credits		82,814,111			80,038,356
Total deferred tax assets		85,300,477			82,400,860

Deferred tax liabilities:
Noncurrent:
Depreciation		(120,353	)		(295,775	)
Total deferred tax liabilities		(120,353	)		(295,775	)

Net deferred tax assets		85,180,124			82,105,085
Less: valuation allowance		(85,180,124	)		(82,105,085	)
Total	$	-		$	-

Note 1 - Summary of Significant Accounting Policies - Valuation Assumptions (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Expected dividend yield	0.00%	0.00%
Expected life (years) (Year)	10 years	10 years
Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0.000	0.000
Minimum [Member]
Expected stock price volatility	84.80%	82.60%
Risk-free interest rate	0.93%	0.13%
Minimum [Member] \| Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input		0.826
Minimum [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0.0042	0.00135
Minimum [Member] \| Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input	5	5
Maximum [Member]
Expected stock price volatility	89.60%	87.00%
Risk-free interest rate	1.66%	1.78%
Maximum [Member] \| Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input		0.87
Maximum [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0.0069	0.0079
Maximum [Member] \| Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input	5.5	5.5

Note 3 - Inventories

12 Months Ended

Dec. 31, 2021